

Referenser Hjärt- och kärlsjukdomar

1. Janusinfo; <http://www.janusinfo.se>
2. <https://vardgivare.skane.se/vardriktlinjer/lakemedel/#43047>
3. Läkemedelsverket; <http://www.lakemedelsverket.se>
4. Socialstyrelsen; <http://www.socialstyrelsen.se>
5. Antikoagulantibehandling vid förmaksflimmer; <https://www.lakemedelsverket.se/sv/behandling-och-forskrivning/behandlingsrekommendationer/sok-behandlingsrekommendationer/antikoagulantibehandling-vid-formaksflimmer>

Hypertoni

- Pearce KA, Furberg CD, Psaty BM, Kirk J. Cost-minimization and the number needed to treat in uncomplicated hypertension. *Amer J Hypertens* 1998;11:618-29.

Ramipril – njursvikt – ej diabetes

- Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in nondiabetic nephropathies with non-nephrotic proteinuria. *Lancet* 1999 Jul 31;354:359-64.

Intensiv terapi – diabetes

- Gaede P, Vedel P, Parving H-H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno 2 randomized study. *Lancet* 1999 Feb 20;353:617-22.

Äldre med systolisk hypertoni – diabetes resp icke diabetes

- Curb JD, Pressel SL, Cutler JA, et al., for the Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. *JAMA* 1996 Dec 18;276:1886-92.

HOPE

- The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. *N Engl J Med* 2000 Jan 20;342:145-53.

RENAAL

- Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Eng J Med* 2001;12:861-869.

IDNT

- Renoprotective effect of the angiotensin-receptoragonist irbesartan with nephropathy due to type II diabetes. *N Engl J Med* 2001;345:851- 60.

IRMA-2

- The effect of irbesartan on the development of diabetic nephropathy in patients with type II diabetes. *N Eng J Med* 2001;345:870-8.

LIFE

- Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002;359:995–1003.

ALLHAT

- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2002;288:2981-2997.

ANBP2

- A comparison of Outcomes with Angiotensin-converting-Enzyme Inhibitors and Diuretics for Hypertension in the Elderly. The Second Australian National Blood Pressure Study Group (ANBP2). *N Engl J Med* 2003;348:583-592.

SCOPE

- The study on cognition and prognosis (SCOPE): principal results of a randomized double-blind intervention trial. *Journal of Hypertension* 2003;21:875-886. SBU rapport nr 170/1, 2004: Måttligt förhöjt blodtryck www.sbu.se

Metaanalys

- Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. *BMJ* 2004;329:828831.

VALUE

- Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. *Lancet* 2004;363:2022-2031.
- Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. *Lancet* 2005;366:1545-53.
- Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet* 2008;366:895-906.

ADVANCE

- Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes (the ADVANCE trial): a randomised controlled trial. *Lancet* 2007;370:829-40.
- Nationella riktlinjer för hjärtsjukvård 2008. www.socialstyrelsen.se

ONTARGET

- Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. The ONTARGET Investigators. *N Engl J Med* 2008;358:1547-59.

TRANSCEND

- Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. The TRANSCEND Investigators. *Lancet* 2008;372:1174-83.

HYVET

- Beckett NS et al. The HYVET Study Group. Treatment of Hypertension in Patients 80 Years of Age or Older. *N Engl J Med* 2008

ACCOMPLISH

- Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *New Engl J Med* 2008;359:2417-28.
- Tandvårds- och läkemedelsförmånsverket. Genomgång av läkemedel mot högt blodtryck 2008. www.tv.se

SPRINT

- Research Group; Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med*. 2015;373(22):2103-16.

HOPE-3

- Yusuf S, et al. "Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease". *The New England Journal of Medicine*. 2016. 374(21):2032-2343

Hjärtsvikt**SOLVD**

- Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. *N Engl J Med* 1991 Aug 1;325(5):293-302.

AIRE

- Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. *Lancet* 1993 Oct 2;342(8875):821-8.

CIBIS II

- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet* 1999 Jan 2;353 (9146):9-13.

MERIT HF

- Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vitovec J, Aldershvile J, Hallinen M, Dietz R, Neuhaus KL, Janosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. *JAMA* 2000 Mar 8;283(10):1295-302.

COPERNICUS

- Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med* 2001 May 31;344(22):1651-8.

RALES

- Pitt B, Zannad F, Remme, WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 Sep 2;341(10):709-17.

DIG

- The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997 Feb 20;336(8):525-33.

CHARM

- Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function and intolerant to ACE inhibitors: the CHARM-Alternative Trial. Lancet 2003;362:772-76
- McMurray JJV, Östergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function treated with an ACE inhibitor: the CHARM-Added trial. Lancet 2003;362:767-71
- Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left ventricular systolic function: the CHARM-Preserved Trial. Lancet 2003;362:777-81.
- Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet 2003;362:759-66
- Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906.

EPHESUS

- Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med 2003;348:1309-21.

EMPHASIS-HF

- Zannad F, et al. "Eplerenone in patients with systolic heart failure and mild symptoms". The New England Journal of Medicine. 2011. 364(1):11-21.

CONFIRM-HF

- Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency Piotr Ponikowski, Dirk J. van Veldhuisen, Josep Comin-Colet, Georg Ertl, Michel Komajda, Viacheslav Mareev, Theresa McDonagh, Alexander Parkhomenko, Luigi Tavazzi, Victoria Levesque, Claudio Mori, Bernard Roubert, Gerasimos Filippatos, Frank Ruschitzka, Stefan D. Anker, European Heart Journal/Aug 2014,DOI: 10.1093/eurheartj/ehu385

PARADIGM-HF

- John J.V., McMurray, M.D., Milton Packer, M.D., Akshay S. Desai, M.D., M.P.H., Jianjian Gong, Ph.D., Martin P. Lefkowitz, M.D., Adel R. Rizkala, Pharm.D., Jean L. Rouleau, M.D., Victor C. Shi, M.D., Scott D. Solomon, M.D., Karl Swedberg, M.D., Ph.D., and Michael R. Zile, M.D. for the PARADIGM-HF Investigators and Committees. N Engl J Med 2014;371:993-1004 September 11, 2014DOI:10.1056/NEJMoa1409077

DAPA-HF

- McMurray et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381:1995-2008

EMPEROR-Reduced

- Milton Packer et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383:1413-1424

Antikoagulantia och trombocythämmare

ISIS-2

- Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988 Aug 13;2(8607):349-60.

RISC

- Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. Lancet 1990 Oct 6;336(8719):827-30.

Juul Möller

- Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992 Dec 12;340(8833):1421-5.

CURE

- Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001 Aug 16;345(7):494-502.
- Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events (CHARISMA). N Engl J Med 2006;354.
- Nationella riktlinjer för hjärtsjukvård 2008. www.socialstyrelsen.se

ACTIVE

- The ACTIVE Investigators. Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation N Engl J Med 2009;360:2066-2078. Triton-TIMI 38
- Wiviott SD et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2007;357:2001-15.

PLATO

- Wallentin L, Harrington R et al, Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes, N Engl J Med 2009;361:1045-1057

PEGASUS

- Bonaca, M.P., et al., Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine, 2015. 372(19): p. 1791-1800

RE-LY

- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151

ROCKET AF

- Patel MR, Mahaffey KW, Garg J, et al Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883-91

ARISTOTLE

- Granger CB, Alexander JH, McMurray JJV, et al Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92

ENGAGE AF-TIMI 48

- Guigliano RP, et al. "Edoxaban versus warfarin in patients with atrial fibrillation". The New England Journal of Medicine. 2013. 369(22):2093-104.
- Barclay, L., Recommendations for Treating Peptic Ulcer Disease Reviewed. American Family Physician, 2007;76:1005-1012
- Miller, T.A., Modern surgical care physiologic foundations and clinical applications, 2006;1:356-357
- Gilard, M., et al., Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost, 2006;4(11):2508-9
- Gilard, M., et al., Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol, 2008;51(3):256-60
- Frere, C., et al., Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol, 2008;101(8):1088-93
- Aubert, R.E., et al., Abstract 3998: Proton Pump Inhibitors Effect on Clopidogrel Effectiveness: The Clopidogrel Medco Outcomes Study. Circulation, 2008;101(8):1088-93
- Ho, P.M., et al., Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome. JAMA 2008;101(8):1088-93
- O'Donoghue, M.L., et al., Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374(694):989-97
- Ho, P.M., et al., Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008;299(5):532-9
- FDA, Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix). 2009. IRF, Ringe klinisk betydning af interaktion mellem PPI og clopidogrel. 2009.

COMPASS

- Eikelboom et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017 Oct 5;377(14):1319-1330
- Anand et al; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Jan 20;391(10117):219-229
- Connolly et al; COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Jan 20;391(10117):205-218

Referenser Hud

Aktinisk keratos

1. de Berker D, McGregor JM, Hughes BR. Guidelines for the management of actinic keratoses. *Br J Dermatol*. 2007;156:222-230. Erratum in: *Br J Dermatol*. 2008;158:873.
2. Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth, Nast A. The natural history of actinic keratosis: a systematic review. *Br J Dermatol*. 2013;169:502-18
3. Ulrich C, Jürgensen JS, Degen A, Hackethal M, Ulrich M, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. *Br J Dermatol*. 2009;161:78-84
4. Siegel J A, Korgavkar K, Weinstock M A. Current perspective on actinic keratosis: a review. *Br J Dermatol* 2017;177:350-358
5. Werner R, Stockfleth E, Connolly S, Correia O, Ermann R et al. Evidence-and consensus-based (S3) Guidelines for the treatment of Actinic Keratosis-International League of Dermatological Societies in cooperation with the European Dermatology Forum. *J Eur Acad Dermatol Venereol* 2015; 29; 2096-2079.
6. Gupta A, Paquet M, Villanueva E, Brintnell W. Interventions for actinic keratosis. *Cochrane Database Syst Rev*. 2012; 12; CD004415.
7. Gupta A, Paquet M.. Network meta-analysis for the outcome 'participant complete clearance' in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review. *Br J Dermatol* 2013;169: 250-259
8. Stockfleth E, Sibbring G, Alarcon I. New topical treatment options for actinic keratosis: a systematic review. *Acta Derm Venereol* 2016; 96: 17-22
9. Morten C A, Szeimies R M, Basset-Sequin N, Calzavara-Pinton P, Gilaberte Y et al. European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: treatment delivery and established indications – actinic keratosis, Bowen's disease and basal cell carcinomas. *J Eur Acad Dermatol Venereol* 2019;33:2225-2238

Akne

10. Claudel J, Auffret N, Leccia M, Poli F, Corvec S, Dréno B. *Staphylococcus epidermidis*: a potential new player in the physiopathology of acne? *Dermatology* 2019;235:287-294.
11. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, et al. Management of acne: a report from a global alliance to improve outcomes in acne. *J Am Acad Dermatol*. 2003;49(1 Suppl):S1-37.
12. Thiboutot D, Gollnick H, Bettoli V, Dreno B, Kang S, et al. New insights into the management of acne: an update from the global alliance to improve outcomes in acne group. *J Am Acad Dermatol* 2009;60(Suppl):S1-50
13. Chernyshov PV, Tomas-Aragones L, Manolache L, Svensson A, Marron SE et al. Which acne treatment has the best influence on health-related quality of life? Literature review by the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes. *J Eur Acad Dermatol Venereol* 2018;32:1410-1419.
14. Fiedler F, Stangl GI, Fiedler E, Taube KM. Acne and Nutrition: A systematic review. *Acta Derm Venereol* 2017;97:7-9.
15. Yang Z, Zhang Y, Mosler E, Hu J, Li H et al. Topical benzoyl peroxide for acne. *Cochrane Database Syst Rev* 2020 CD011154
16. Liu H, Yu H, Xia J, Liu L, Liu G et al. Topical azelic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne. *Cochrane Database Syst Rev* 2020 CD011368
17. Williams HC, Dellavalle RP, Garner S. Acne vulgaris. *Lancet* 2012;379:361-372.
18. Behandling av akne - behandlingsrekommendation. Information från Läkemedelsverket , 2014; 4: 15-24
19. Hayran Y, Incel Uysal P, Öktem A, Aksoy G, Akdogan N, Yalcin B. Factors affecting adherence and patient satisfaction with treatment: a cross sectional study of 500 patients with acne vulgaris. *J Dermatol Treat* 2019 May 28;1-6 Epub ahead of print
20. Koo EB, Petersen TD, Kimball AB. Meta-analysis comparing efficacy of antibiotics versus oral contraceptives in acne vulgaris. *J Am Acad Dermatol* 2014;71:450-459.
21. Samuels D, Rosenthal R, Lin R, Chaudhari S, Natsuaki M. Acne vulgaris and risk of depression and anxiety: A meta-analytic review. *J Am Acad Dermatol* 2020;83:532-41.

Rosacea

22. van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MMD, Charland L. Interventions for rosacea. *Cochrane Database Syst Rev*, 2015;CD 003262
23. Alexis A, Callender V, Baldwin H, Desai S, Rendon M et al. Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: Review and clinical practice experience. *J Am Acad Dermatol* 2019;80:1722-9.
24. Taieb A, Ortonne J, Ruzicka T, Roszkiewicz J, Berth-Jones J, et al. Ivermectin phase III study group. Superiority of ivermectin 1 % cream over metronidazole 0.75 % cream in treating inflammatory lesions of rosacea: randomized, investigator-blinded trial. *Br J Dermatol* 2015;172:1103-10.
25. Stein Gold L, Kircik L, Fowler J, Jackson J, Tan J, et al. Ivermectin phase III study group. Long-term safety of ivermectin 1 % cream vs azelaic acid 15 % gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. *J Drugs Dermatol* 2014;13:1380-6.
26. Feaster B, Cline A, Feldman S, Taylor S. Clinical effectiveness of novel rosacea therapies. *Curr Opin Pharmacol* 2019;46:14-18.
27. Husein-ElAhmed H, Steinhoff M. Efficacy of topical ivermectin and impact on quality of life in patients with papulopustular rosacea: A systematic review and meta-analysis. *Dermatologic Therapy* 2020;33:e13203.
28. Van Zuuren E, Fedorowicz Z, Tan J, van der Linden, Arents B et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. *Br J Dermatol* 2019;181:65-79.

Perioral dermatit

29. Tolaymat L, Hall M. Perioral Dermatitis. In: *StatPearls* (Internet). Treasure Island (FL): StatPearls Publishing; May 3, 2020

Atopisk dermatit

30. Williams H. Established corticosteroid creams should be applied only once daily in patients with atopic eczema. *BMJ* 2007;334:1272-1273.
31. Behandling av atopiskt eksem. Behandlingsrekommendation. Information från Läkemiddelsverket 2005; 2: 1-12.
32. Svedman C, Svensson Å. Atopisk dermatit – utredning och behandling *Allergi i Prakxis* 2016;1:6-13.
33. Schmitt J, von Kobyletzki L, Svensson Å, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin-inhibitors for atopic eczema: systematic review and meta-analysis of randomised controlled trials. *Br J Dermatol* 2011;164:415- 428
34. Francis NA, Ridd MJ, Thomas-Jones E, Shepherd V, Butler CC, Hood K, et al. A randomized placebo-controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the children with eczema, Antibiotic Management (CREAM) study. *Health Technol Assess* 2016;20:1-84.
35. Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, Williams HC. Interventions to reduce *Staphylococcus aureus* in the management of atopic eczema: an updated Cochrane review. *Br J Dermatol*. 2010;163:12-26.
36. Thomas K, Bradshaw L, Sach T, Cowdell F, Batchelor J et al. Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial. *Health Technol Assess* 2017;21:1-260.
37. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. *J Eur Acad Dermatol Venereol* 2018;32:657-682.
38. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. *J Eur Acad Dermatol Venereol* 2018;32:850-878.
39. Vestergaard C, Wollenberg A, Barbarot S, Christen-Zaech S, Deleuran M et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. *J Eur Acad Dermatol Venereol* 2019;33:1644-1659.
40. Proudfoot L., Powell A., Avis S, Barbarot S, Svensson A et al. The European treatment of severe atopic eczema in children taskforce (TREAT) survey. *Br J Dermatol* 2013;169:901-909.
41. Simon D, Bieber T. Systemic therapy for atopic dermatitis. *Allergy* 2014;69:46-55. *Dermatology*. 2017;233:344-357.
42. Simpson EL, Bruin-Weller M, Flohr C, Ardern-Jones MR, Barbarot S et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. *J Am Acad Dermatol* 2017; 77:623-633.

43. Snast I, Reiter O, Hodak E, Friedland R, Mimouni D et al. Are biologics efficacious in atopic dermatitis? A systematic review and meta-analysis. *Am J Clin Dermatol* 2018;19:14-165.
44. Regionala riktlinjer systembehandling svår atopisk dermatit https://vardgivare.skane.se/siteassets/1.-vardriktlinjer/lakemedel/riktlinjer/lakemedelsriktlinjer/systemisk-behandling-av-atopisk-dermatit_reviderad-riktlinje-2019-11-05.pdf

Handeksem

45. Lindberg. M. Meding B. Stenberg B. Svensson Å. Handeksem är en folksjukdom som påverkar livskvalitet och arbetsförmåga. *Läkartidningen* 2013;110:23-29.
46. Kadyk DL, McCarter K, Achen F, Belsito DV. Quality of life in patients with allergic contact dermatitis. *J Am Acad Dermatol* 2003;49:1037-48.
47. Hamnerius N, Svedman C, Bergendorff O, Björk J, Bruze M et al. Wet work exposure and hand eczema among healthcare workers - a cross-sectional study. *Br J Dermatol* 2018;178:452-461.
48. Christoffers W, Coenraads P, Svensson Å, Diepgen T, Dickinson-Blok J et al. Interventions for hand eczema. *Cochrane Database Syst Rev* 2019 Apr 26;4:CD004055.
49. National Klinisk retningslinje för behandling af håndeksem Sundhedsstyrelsen, Danmark 2016-10-04
50. Elsner P. Expert opinions in dermatology. *J Dtsch Dermatol Ges* 2019;17:810-823.

Seborroiskt eksem

51. Hay RJ, Malassezia, dandruff and seborrhoeic dermatitis: an overview. *Br J Dermatol*. 2011;165: Suppl 2:2-8.
52. Elgash M, Dlova N, Ogunleye T, Taylor S. Seborrheic dermatitis in skin of color: clinical considerations. *J Drugs Dermatol* 2019;18:24-27.
53. Hald M, Arendrup M, Svejgaard E, Lindskov R, Foged E et al. Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases. *Acta Derm Venereol* 2015;95:12-19.
54. Naldi L, Diphooorn J. Seborrhoeic dermatitis of the scalp. *BMJ Clin Evid*. 2015;1713.
55. Okokon EO, Verbeek JH, Ruotsalainen JH, Ojo OA, Bakhoya VN. Topical antifungals for seborrhoeic dermatitis (Review). *The Cochrane Library* 2015, Issue 5.

Mjukgörande medel vid torr hud

56. Lind J, Bradley M. Clinical Effectiveness of moisturizers in atopic dermatitis and related disorders. A systematic review. *Am J Clin Dermatol* 2015;16:341-59.
57. van Zuuren EJ, Fedorowicz Z, Christensen, R, Lavrijsen APM, Arents BWM. Emollients and moisturisers for eczema. *Cochrane Database of Systematic Reviews* 2017, Issue 2. CD012119
58. Norrliid H, Hjalte F, Lundqvist A, Svensson A and Ragnarson Tennvall G. Cost-effectiveness of maintenance treatment with a barrier-strengthening moisturizing cream in patients with atopic dermatitis in Finland, Norway and Sweden. *Acta Derm Venereol* 2016; 96; 173-176
59. Skjerven H, Rehbinder E, Vettukattil R, LeBlanc M, Granum B et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. *Lancet* 2020 Epub ahead of print
60. Chalmers JR, Haines RH, Bradshaw LE. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. *Lancet* 2020 Epub ahead of print
61. Faergemann J, Olsson P, Svensson Å. A randomized, single-blind comparison of the efficacy, tolerability and cosmetic acceptance of propylless or fenuril treatment of patients with dry skin. *Acta Derm Venereol*. 2009; 89: 305-7.

Psoriasis

62. Meding B. Normal standards for dermatological health screening at places at work. *Contact Dermatitis* 1992;27:269-70.
63. Lindberg M, Isacson D, Bingefors K. Self-reported skin diseases, quality of life and medication use: a nationwide pharmaco-epidemiological survey in Sweden. *Acta Derm Venereol* 2014;94:188-91.
64. Michalek M, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. *J Eur Acad Dermatol Venereol* 2017;31:205-212.
65. Nya behandlingsmetoder för psoriasis och psoriasisartrit – Läkemedelsverket. 2019

66. Nationella riktlinjer för vård vid psoriasis. Socialstyrelsen 2019. <https://www.socialstyrelsen.se/regler-och-riktlinjer/nationella-riktlinjer/publicerade-riktlinjer/psoriasis/>
67. Svenska Sällskapet för Dermatologi och Venereologis behandlingsrekommendationer för systemisk behandling av psoriasis 2020

Kronisk urtikaria

68. Zuberbier T et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. *Allergy* 2018;73:1393-1414.
69. Radonjic-Hoesli S, Scherer K, Micalletto S, Schmid-Grendelmeier P, Bircher A et al. Urticaria and angioedema: an update on classification and pathogenesis. *Clin Rev Allergy Immunol* 2018;54:88-101.
70. Bansal C, Bansal A. Stress, pseudoallergens, autoimmunity, infection and inflammation in chronic spontaneous urticaria. *Allergy Asthma Clin Immunol* 2019;15:56.
71. Krause K et al. How not to miss autoinflammatory diseases masquerading as urticaria. *Allergy*. 2012;67:1465-74.

Kronisk klåda

72. Weisshaar E, Szepietowski J, Dalgard F, Garcovich S, Gieler U et al. European S2k guideline on chronic pruritus. *Acta Derm Venereol* 2019;99:469-506.
73. Reich A, Ständer S, Szepietowski JC. Drug-induced pruritus: a review. *Acta Derm Venereol*. 2009;89:236-244.
74. Huang A, Kaffenberger B, Reich A, Szepietowski J, Ständer S et al. Pruritus associated with commonly prescribed medications in a tertiary care center. *Medicines (Basel)* 2019;6:84.
75. Yosipovitch G, Bernhard J. Clinical practice. Chronic pruritus. *N Engl J Med*. 2013;368:1625-34.
76. Legat FJ. Importance of phototherapy in the treatment of chronic pruritus. *Hautarzt*. 2018;69:631-640.
77. Simon D, Bieber T. Systemic therapy for atopic dermatitis. *Allergy* 2014;69:46-55.
78. Spring P, Gschwind I, Gilliet M. Prurigo nodularis: retrospective study of 13 cases managed with methotrexat. *Clin Exp Dermatol* 2014;39:468-73.
79. Maley A, Swerlick R. Azathioprine treatment of intractable pruritus: A retrospective review. *J Am Acad Dermatol*. 2015;73:439-43.
80. Fernandez JM, Fernandez AP, Lang DM. Biologic Therapy in the Treatment of Chronic Skin Disorders. *Immunol Allergy Clin North Am*. 2017;37:315-327.
81. Zeidler C, Tsianakas A, Pereira M, Ständer H, Yosipovitch G, Ständer S. Chronic prurigo of nodular type: A review *Acta Derm Venereol* 2018;98:173-179.
82. Pereira M, Ständer S. Therapy for pruritus in the elderly: a review of treatment developments. *Expert Opin Pharmacother* 2018;19:443-450.

Impetigo

83. Koning S, van der Sande R, Verhagen AP, van Suijlekom-Smit LW, Morris AD et al. Interventions for impetigo. *Cochrane Database Syst Rev*. 2012;1:CD003261.
84. Hud- och mjukdelsinfektion. Läkemedelsverket 2018 <https://www.lakemedelsverket.se/hudmjukdelsinfektion>
85. Impetigo: antimicrobial prescribing. NICE guideline. Published: 26 February 2020 www.nice.org.uk/guidance/ng153

Klamydiainfektion

86. Low N, Egger M, Sterne JA, Harbord RM, Ibrahim F et al. Incidence of severe reproductive tract complications associated with diagnosed genital chlamydial infection: the Uppsala Women's Cohort Study. *Sex Transm Infect*. 2006;82:212-8
87. Kumamoto Y, Matsumoto T, Fujisawa M, Arakawa S. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urogenital and oral specimens using the cobas® 4800, APTIMA Combo 2® TMA, and ProbeTec™ ET SDA assays. *Eur J Microbiol Immunol (Bp)*. 2012;2:121-7.

88. Svenska Sällskapet för Dermatologi och Venereologi (SSDV:s) rekommendationer för behandling av sexuellt överförbara infektioner (STI) uppdaterad, version 5, 2019.
89. Geisler WM, Uniyal A, Lee JY, Lensings S, Johnson S et al. Azithromycin versus Doxycycline for urogenital Chlamydia trachomatis infection. *N Engl J Med* 2015;373:2512-2521.
90. Brunham RC, Gottlieb SL, Paavonen J, Pelvic inflammatory disease. *N Engl J Med* 2015;372:2039-2048.

Kondylom

91. Ljubojevic S, Skerlev M. HPV-associated diseases. *Clin Dermatol* 2014;32:227-34.
92. Stratton K, Culkin D. A contemporary review of HPV and penile cancer. *Oncology (Williston Park)* 2016;30:245-9.
93. Harden M, Munger K. Human papillomavirus molecular biology. *Mutat res rev mutat res* 2017; 772:3-12.
94. Bertolotti A, Milpied B, Fouéré S, Cabié A, Dupin N et al. Local management of anogenital warts in immunocompetent adults: Systematic review and pooled analysis of randomized-controlled trial data. *J Am Acad Dermatol* 2019;81:1203-1204.
95. O'Mahony C, Gomberg M, Skerlev M, Alraddadi A, Las Heras-Alonso M et al. Position statement for the diagnosis and management of anogenital warts. *J Eur Acad Dermatol Venereol.* 2019;33:1006-1019.
96. Lamb F, Herweijer E, Ploner A, Uhnoo I, Sunström K et al. Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study. *BMJ Open* 2017;7:e015021
97. Herweijer E, Ploner A, Sparén P. Substantially reduced incidence of genital warts in women and men six years after HPV vaccine availability in Sweden. *Vaccine* 2018;36:1917-1920.

Huvudlöss

98. Behandling av huvudlöss – behandlingsrekommendation. Information från Läkemiddelsverket 2019;30(3):1-5.
99. Sanchezruiz W, Nuzum D, Kouzi S. Oral ivermectin for the treatment of head lice infestation. *Am J Health-Syst Pharm* 2018;75:937-43.

Flatlöss

100. Coates S, Thomas C, Chosidow O, Engelman D, Chang A. Ectoparasites. Pediculosis and tungiasis. *J Am Acad Dermatol* 2020;82:551-69.

Skabb

101. Bernigaud C, Fischer K, Chosidow O. The management of scabies in the 21 Century: past, advances and potentials. *Acta Derm Venereol* 2020,100: Epub ahead of print.
102. Regionala riktlinjer se <http://vardgivare.skane.se/vardriktlinjer/lakemedel>

Mykoser

103. Panthagani AP, Tidman MJ. Diagnosis directs treatment in fungal infections of the skin *Practitioner* 2015;259:25-29.
104. El-Gohary M, van Zuuren E, Fedorowicz Z, Burgess H, Doney L ET AL. Topical antifungal treatments for tinea cruris and tinea corporis. *Cochrane Database Syst Rev* 2014;8:CD009992.
105. Lines A, Vardi-Flynn I, Searle C. Recurrent vulvovaginal candidiasis. *BMJ* 2020;369:m1995.
106. Chen X, Jiang X, Yang M, González U, Lind X. Systemic antifungal therapy for tinea capitis in children. *Cochrane Database Syst Rev*;5:CD004685.
107. Kreijkamp-Kaspers S, Hawke K, Guo L, Kerin G, Bell-Syer S. Oral antifungal medication for toenail onychomycosis. *Cochrane Database Syst Rev*:7:CD010031.
108. Lipner S, Scher R. Onychomycosis: Treatment and prevention of recurrence. *J Am Acad Dermatol*;80:853-867.

Hidradenit

109. Killasli H, Sartorius K, Emtestam L, Svensson Å. Hidradenitis suppurativa in Sweden: A registry-based cross-sectional study of 13538 patients. *Dermatology* 2020;236:281-288.
110. Chemyshov P, Zouboulis C, Tomas-Aragones L, Jemec G, Svensson A et al. Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on quality of life and patient-oriented outcomes and acne, rosacea and hidradenitis suppurativa. *J Eur Acad Dermatol Venereol* 2019;33:1633-1643.
111. Zouboulis CC et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. *J Eur Acad Dermatol Venereol.* 2015; 29:619-44.
112. Woodruff CM et al. Hidradenitis suppurativa: A guide for the practicing physician. Review. *Mayo Clin Proc.* 2015; 90: 1679-1693.
113. Riis PT et al. Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): A case series. *J Am Acad Dermatol.* 2016; 75:1151-5.
114. Behandling av akne-behandlingsrekommendation. Information från Läkemedelsverket 4: 2014.
115. Zouboulis C, Bechara F, Dickinson-Blok J, Gulliver W, Horváth B et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group. *J Eur Acad Dermatol Venereol* 2019;33:19-31.
116. Goldburg S, Strober B, Payette M. Hidradenitis suppurativa. Current and emerging treatments. *J Am Acad Dermatol* 2020;82:1061-82.
117. Orenstein L, Nguyen T, Damiani G, Sayed C, Jemec G et al. Medical and surgical management of hidradenitis suppurativa: a review of international treatment guidelines and implementation in general dermatology practice. *Dermatology* 2020;14:1-20. Pub ahead of print.
118. Regionala riktlinjer 2020-12-31 <https://vardgivare.skane.se/siteassets/1.-vardriktlinjer/lakemedel/riktlinjer/lakemedelsriktlinjer/hidradenitis-suppurativa-180123.pdf>

Referenser Infektionssjukdomar

Infektion

1. Leibovitz E, Greenberg D, Piglansky L, Raiz S, Porat N, Press J, et al. Recurrent acute otitis media occurring within one month from completion of antibiotic therapy: relationship to the original pathogen. *Pediatr Infect Dis J*. 2003 Mar;22(3):209-16.
2. van Dongen TM, van der Heijden GJ, Venekamp RP, Rovers MM, Schilder AG. A trial of treatment for acute otorrhea in children with tympanostomy tubes. *N Engl J Med* 2014 Feb 20;370(8):723-33.

Referenser Kognitiva sjukdomar

(1) <https://vardgivare.skane.se/vardriktlinjer/kognitiva-sjukdomar-och-demens/>

(2) <https://www.demenscentrum.se/Arbeta-med-demens/Verktyg>

- Atri A, Shaughnessy LW et al. Long-term course and effectiveness of combination therapy in Alzheimer disease. *Alzheimer Dis Assoc Disord* 2008;22: 209-21.
- Ballard CG, Waite J et al. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. *Cochrane Database Syst Rev* 2006, Issue 1. Art. No: CD003476. DOI: 10.1002/14651858.CD003476.pub2.
- Health Quality Ontario 2013. Vitamin B and cognitive function: an evidence-based analysis. *Ont Health Technol Assess Ser.* 2013 Nov 1;13(23):1-45.
- Howard R, McShane R et al. Donepezil and memantine for moderate-to-severe Alzheimer's Disease, *NEJM*, 2012; 366: 893-903. DOI: 10.1056/NEJMoa1106668
- Kognitiv medicin. Lars-Olof Wahlund, Christer Nilsson, Anders Wallin (red.) Norstedt 2011
- Lopez OL, Becker JT et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. *J Neurol Neurosurg Psychiatry* 2009; 80: 600-7.
- Läkemedelsverket. Behandling och bemötande vid Beteendemässiga och Psykiska Symtom vid Demenssjukdom – "BPSD". Information från läkemedelsverket 5: 2008. www.lakemedelsverket.se
- McShane R1, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, Maayan N, Ware J, Debarros J. Memantine for dementia. *Cochrane Database Syst Rev.* 2019 Mar 20;3:CD003154. doi: 10.1002/14651858.CD003154.pub6.
- NICE 2011. Donepezil, galantamine, rivastagmine and memantine for the treatment of Alzheimer's disease. NICE technology appraisal guidance 217.
- Region Skåne 2015. Vårdprogram för sjukdomar med varaktigt kognitiv svikt. <http://vardgivare.skane.se/vardriktlinjer/medicinska-omraden/kognitiva-sjukdomar-och-demens/>
- SBU Statens beredning för medicinsk utvärdering. 2006. Demenssjukdomar. Rapportnr 172.
- Smith AD; Refsum H, Bottiglieri T, Fenech M, Hooshmand B, McCaddon A, Miller JW, Rosenberg IH, Obeid R. "Homocysteine and Dementia: An International Consensus Statement", *J Alheimers Dis*, 2018; 62(2):561-570.
- Socialstyrelsen. 2010. Nationella riktlinjer för vård och omsorg vid demenssjukdom. Art. No 2010-5-1.
- Socialstyrelsen. 2017. Indikatorer för god läkemedelsterapi hos äldre. Art. No. 2017-6-7. www.socialstyrelsen.se
- Socialstyrelsen. 2019. Ett standardiserat insatsförlopp vid demenssjukdom – en modell för mångprofessionell samverkan för personcentrerad vård och omsorg vid demenssjukdom. Art No. 2019-6-22.
- Vägverkets författningssamling, VVFS 2008:166. Vägverkets föreskrifter om ändring i föreskrifterna (VVFS 2008:158) om medicinska krav för innehav av körkort mm, 10:e kapitlet demens och andra kognitiva störningar

Referenser Lipidrubbing

1. Socialstyrelsen. Nationella riktlinjer för hjärtsjukvården. 2008, kompletterade 2011. <https://www.socialstyrelsen.se/regler-och-riktlinjer/nationella-riktlinjer/slutliga-riktlinjer/hjartsjukvard/>
2. Socialstyrelsen. Nationella riktlinjer för strokesjukvård. 2009, kompletterade 2011. <https://www.socialstyrelsen.se/regler-och-riktlinjer/nationella-riktlinjer/slutliga-riktlinjer/stroke/>
3. Socialstyrelsen. Nationella riktlinjer för diabetesvården. 2010. <https://www.socialstyrelsen.se/regler-och-riktlinjer/nationella-riktlinjer/slutliga-riktlinjer/diabetes/>
4. Läke medelsverket. Förebyggande av aterosklerotisk hjärt-kärlsjukdom. 2006;3(17).
5. Reiner Z, Catapano AL, De Backer G et al. ESC/EASEuropean Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011 Jul;32(14):1769-818. <http://www.escardio.org/guidelines>
6. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2012 Jul;33(13):1635-701. <http://www.escardio.org/guidelines>
7. Heart Protection Study Collaborative Group. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: A randomised controlled trial. Lancet 2011; 387:2013-20.
8. Paciaroni M, Hennerici M, Agnelli G, Bogousslavsky J. Statins and stroke prevention. Cerebrovasc Dis 2007;24(2-3):170-82.
9. Collins R, Armitage J, Parish S et al (HPS). Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004 Mar 6;363(9411):757-67.
10. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012 Aug 11;380(9841):581-90.
11. Taylor F, Ward K, Moore THM, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011; 1 (CD004816).
12. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008 Jan 12;371(9607):117-25.
13. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010; 375:1875-84.
14. Ray KK, Seshasai SR, Erqou S et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 2010;170(12):1024-31.
15. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376. doi:10.1136/bmj.b2376.
16. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering in 20 536 high-risk individuals: a randomized placebocontrolled trial. Lancet 2002;360:7-22.
17. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376: 1670–81.
18. Armitage J, Bowman L, Wallendszus K et al (SEARCH). Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010 Nov 13;376(9753):1658-69.
19. Emberson J, Bennett D, Link E et al. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study Lancet 2011 Feb 5;377(9764):469-76.
20. Afilalo J, Duque G, Steele R et al. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Cardiol 2008;51(1):37-45.
21. Ridker PM, Danielson E, Fonseca FA et al (JUPITER). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359(21):2195-207.

22. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 2004;350:1495-504.
23. Di Sciascio G, Patti G, Pasceri V et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. *J Am Coll Cardiol* 2009;54:558-65.
24. Patti G, Cannon CP, Murphy SA et al. Clinical Benefit of Statin Pretreatment in Patients Undergoing Percutaneous Coronary Intervention/ Clinical Perspective: A Collaborative Patient-Level Meta-Analysis of 13 Randomized Studies. *Circulation* 2011;123:1622-1632.
25. Kastelein JJ, Akdim F, Stroes ES et al (ENHANCE). Simvastatin with or without ezetimibe in familial hypercholesterolemia. *N Engl J Med* 2008;358(14):1431-43.
26. Rossebø AB, Pedersen TR, Boman K et al (SEAS). Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. *N Engl J Med* 2008;359(13):1343-56.
27. Baigent C, Landray MJ, Reith C et al (SHARP). The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet* 2011 Jun 25;377(9784):2181-92.
28. Boden WE, Probstfield JL, Anderson T et al (AIM-HIGH). Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. *N Engl J Med* 2011 Dec 15;365(24):2255-67.
29. Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statins trials. *Lancet* 2010; 375:735-42.
30. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy. A Meta-analysis. *JAMA* 2011;305:2556-64.
31. Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M et al. Metaanalysis of drug-induced adverse events associated with intensive-dose statin therapy. *Clin Therapy* 2007 Feb;29(2):253-60.
32. Kjekshus J, Apetrei E, Barrios V et al (CORONA). Rosuvastatin in older patients with systolic heart failure. *N Engl J Med* 2007;357(22):2248-61.
33. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. *Am J Cardiol* 2006;97(8A):77C-81C.
34. Amarenco P, Bogousslavsky J, Callahan A et al (SPARCL). High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med* 2006;355(6):549-59.
35. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. *Int J Cancer* 2007;120(4):833-43.
36. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. *JAMA* 2006;295(1):74-80.
37. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial. *BMC Med* 2005;3:6.
38. Christopher P. Cannon, M.D., Michael A. Blazing, M.D., Robert P. Giugliano, M.D et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. *N Engl J Med* 2015; 372:2387-2397.
39. Att förebygga aterosklerotisk hjärt-kärlsjukdom med läkemedel – behandlingsrekommendation Information från Läkemedelsverket 2014: (25) 5
40. HOPE-3 Yusuf S, et al. "Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease". *The New England Journal of Medicine*. 2016. 374(21):2032-2343
41. Sabatine MS, Giugliano RP, Keech AC, et al;FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. Epub 17 mar 2017. doi: 10.1056/NEJMoa1615664.
42. Schwartz et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med*. 2018;379(22):2097-107.

Referenser Matsmältningsorgan

Dyspepsi

Bakgrund

- (1) Nationell riktlinje 2019: Outredd dyspepsi, okomplicerade duodenal- och ventrikelsår samt funktionell dyspepsi. Publicerat under riktlinjer på Svensk Gastroenterologisk Förenings hemsida, <https://svenskgastroenterologi.se/riktlinjer/luminal-gastroenterologi/>

Standardiserat vårdförlopp för matstrups- och magsäckscancer

- <http://www.cancercentrum.se/syd/cancerdiagnoser/matstrupe-och-magsack/vardforlopp/>
- (2) Kortversion för primärvården (AKO-riktlinjer) för matstrups- och magsäckscancer, <https://vardgivare.skane.se/vardriktlinjer/cancer/#11542>

Helicobacter pylori (Hp)

- Dyspepsi och reflux, en systematisk litteraturoversikt, SBU-rapport 2007
- (1) Nationell riktlinje 2019: Outredd dyspepsi, okomplicerade duodenal- och ventrikelsår samt funktionell dyspepsi. Publicerat under riktlinjer på Svensk Gastroenterologisk Förenings hemsida <https://svenskgastroenterologi.se/riktlinjer/luminal-gastroenterologi/>

Ulcusjukdom orsakad av COX-hämmare

- Blödande magsår, en systematisk litteraturoversikt, SBU-rapport maj 2011
- Coxib and Traditional NSAID Trialists' Collaboration. The Lancet ;Early Online Publication, 30 May 2013, Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
- Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016 Dec 29;375(26):2519-29

Dyspepsi-preparatval

- LäkeMedelsverket: LäkeMedelsmonografi av Nexium (esomeprazol), Tryckt version: 2000;11.
- (1) Nationell riktlinje 2019: Outredd dyspepsi, okomplicerade duodenal- och ventrikelsår samt funktionell dyspepsi. Publicerat under riktlinjer på Svensk Gastroenterologisk Förenings hemsida <https://svenskgastroenterologi.se/riktlinjer/luminal-gastroenterologi/>
- STW5 (lberogast) - a safe and effective standard in the treatment of functional gastrointestinal disorders.
- Ottillinger B, Storr M, Malfetheiner P, Allescher AD. Wien Med Woshenschr. 2013 Feb;163(3-4):65-72.

Utsättning av PPI

- Backman L, Schmidt D, Vitols S. Protonpumpshämmare misstänks ge allvarliga biverkningar. Försiktigare förskrivning bör övervägas och på korrekta indikationer. Läkartidningen nr 16 2013; 110, 828-31.
- Lundgren C. Protonpumpshämmare A02BC. FAS UT 3, s 26-33.
- (3) "Att sluta med protonpumpshämmare; Patientinformation framtagen av terapigrupp Gastroenterologi Region Skåne, version 2019; <https://vardgivare.skane.se/vardriktlinjer/lakemedel/#13487>

Utredning av patienter med ändrade avföringsvanor

Standardiserat vårdförlopp för tjocktarms- och ändtarmscancer

- <https://www.cancercentrum.se/samverkan/cancerdiagnoser/tjocktarm-andtarm-och-anal/tjock-och-andtarm/vardprogram/>
- (4) Kortversion för primärvården (AKO-riktlinjer) tjocktarms- och ändtarmscancer <https://vardgivare.skane.se/vardriktlinjer/cancer/#11542>

Irritabel Bowel Syndrome (IBS)

- Rom IV kriterier: Lacy et al. Gastroenterology 2016,150:1393-1407.
- Bodil Ohlsson, Medicinkliniken, Skånes universitetssjukhus, Malmö; LäkeMedelsboken avsnittet om Tarmkanalens funktionsrubbnings; <https://lakemedelsboken.se/>
- LäkeMedelsboken; <https://lakemedelsboken.se/>
- IBS-guidelines Svensk Gastroenterologisk Förening (SGF) Sammanfattning: <https://svenskgastroenterologi.se/wp-content/uploads/2019/12/2009-ibs.pdf>

- A meta-analysis of the therapeutic effects of amitriptyline for treating irritable bowel syndrome. Chao GQ, Zhang S. Intern Med 2013;52(4):419-24.
- Selective serotonin reuptake inhibitors for the treatment of irritable bowel syndrome. Bundeff AW, Woodis CB. Ann Pharmacother 2014 Jun;48(6):77-84.
- STW5 (Iberogast) -a safe and effective standard in the treatment of functional gastrointestinal disorders. Ottillinger B, Storr M, Malfetheiner P, Allescher AD. Wien Med Wochenschr. 2013 Feb;163(3-4):65-72.
- SPC Colpermin (pepparmyntsolja): <https://www.fass.se/LIF/product?userType=0&nplld=20110316000015&docType=6&scrollPosition=280>
- TLV-beslut Colpermin (pepparmyntsolja): <https://www.tlv.se/beslut/beslut-lakemedel/avslag-och-uteslutningar/arkiv/2019-06-27-colpermin-ing-ar-inte-i-hogkostnadsskyddet.html>
- Eluxadolin (Truberzi): Risk för pankreatit och spasm i Oddis sfinkter (SPC) https://www.ema.europa.eu/en/documents/product-information/truberzi-epar-product-information_sv.pdf

Mikroskopisk kolit

- Medicinska mag- och tarmsjukdomar. Henry Nyhlin (red), Studentlitteratur 2008; 351-8.

Divertikulos och divertikulit

- Gastroenterologi och hepatologi av Rolf Hultcrantz mfl (2011), kapitel 28.
- Internetmedicin.se , avsnitt om divertikulit: <http://www.internetmedicin.se/page.aspx?id=1477>

Exokrin pankreasinsufficiens

- Internetmedicin, avsnitt om Exokrin pancreasinsufficiens (EPI): <http://www.internetmedicin.se/page.aspx?id=5927>
- Löhr et al. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European Gastroenterol J. 2017 Mar;5(2):153-199

Anemi

Järnbristanemi

- Anemia in Inflammatory Bowel Diseases. Christoph Gasche (red), UNI-MED Verlag AG 2008; 37-53
- Ferric Maltol Is Effective in Correcting Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: Results from a Phase-3 Clinical Trial Program, Gasche Christoph et al, Inflamm Bowel Dis. 2015 Mar; 21(3): 579–588. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342319/>
- Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long term extension data from a Phase 3 study, Schmidt C et al; AEGIS Study Group, Aliment Pharmacol Ther. 2016 Aug; 44(3):259-70. doi: 10.1111/apt.13665. Epub 2016 May 29. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089582/>
- TLV-beslut Feraccru: <https://www.tlv.se/beslut/beslut-lakemedel/begransad-subvention/arkiv/2018-02-23-feraccru-ingar-i-hogkostnadsskyddet-med-begransning.html>
- FASS-text Feraccru november 2019: <https://www.fass.se/LIF/product?userType=0&nplld=20150203000025&docType=3&scrollPosition=587>

Referenser Munhålan och Tandvårdslistan

Medel mot karies

1. SBU. Att förebygga karies. En systematisk litteraturoversikt. Stockholm: Statens beredning för medicinsk utvärdering (SBU); 2002. SBU-rapport nr 161. ISBN 91-87890-81-X.
2. SBU. Karies – diagnostik, riskbedömning och icke-invasiv behandling. En systematisk litteraturoversikt. Stockholm: Statens beredning för medicinsk utvärdering (SBU); 2007. SBU-rapport nr 188. ISBN 978-91-85413-21-8.
3. Socialstyrelsen. National Guidelines for Adult Dental Care 2011, <https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/nationella-riktlinjer/2011-5-1.pdf> (25 oktober 2020).
4. Walsh T, Worthington HV, Glenny AM, Appelbe P, Marinho VCC, Shi X. Fluoride toothpastes of different concentration for preventing dental caries in children and adolescents. *Cochrane Database of Systematic Reviews*, 2019;3:CD007868.
5. Ekstrand KR1, Poulsen JE, Hede B, Twetman S, Qvist V, Ellwood RP. A randomized clinical trial of the anti-caries efficacy of 5,000 compared to 1,450 ppm fluoridated toothpaste on root caries lesions in elderly disabled nursing home residents. *Caries Res*, 2013;47(5):391-8.
6. Singh, A. and B.M. Purohit, Caries Preventive Effects of High-fluoride vs Standard-fluoride Toothpastes - A Systematic Review and Meta-analysis. *Oral Health Prev Dent*, 2018;16(4): 307-314.
7. Nordström A1, Birkhed D. Preventive effect of high-fluoride dentifrice (5,000 ppm) in caries-active adolescents: a 2-year clinical trial. *Caries Res*, 2010;44(3):323-31.
8. Toumba, K.J., et al., Guidelines on the use of fluoride for caries prevention in children: an updated EAPD policy document. *Eur Arch Paediatr Dent*, 2019;20(6):507-516.
9. Moberg Sköld U, Birkhed D, Borg E, Petersson LG. Approximal caries development in adolescents with low to moderate caries risk after different 3-year school-based supervised fluoride mouth rinsing programmes. *Caries Res*, 2005;39:529-535.
10. Twetman, S., et al., Caries-preventive effect of sodium fluoride mouthrinses: a systematic review of controlled clinical trials. *Acta Odontol Scand*, 2004;62(4):223-30.
11. Marinho, V.C., et al., Fluoride mouthrinses for preventing dental caries in children and adolescents. *Cochrane Database Syst Rev*, 2016;7:CD002284.
12. Wyatt CCL, MacEntee MI. Caries management for institutionalized elders using fluoride and chlorhexidine mouthrinses. *Community Dent Oral Epidemiol*; 2004;32:322-328.
13. Pitts, N., et al., Post-brushing rinsing for the control of dental caries: exploration of the available evidence to establish what advice we should give our patients. *Br Dent J*, 2012; 212(7):315-20.
14. Marinho, V.C., et al., Fluoride gels for preventing dental caries in children and adolescents. *Cochrane Database Syst Rev*, 2015;6:CD002280.
15. Marinho, V.C., et al., Fluoride varnishes for preventing dental caries in children and adolescents. *Cochrane Database Syst Rev*, 2013;7:CD002279.

Medel för salivstimulering

1. LeVeque FG, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. *J Clin Oncol*. 1993;11:1124-1131.
2. Vivino FB, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. *Arch Intern Med* 1999;159:174-81.

Antiseptiska medel för lokal behandling

1. SBU. Chronic periodontitis – prevention, diagnosis and treatment. Stockholm: Swedish Council on Health Technology Assessment in Health Care (SBU); 2004. SBU report no 169 (in Swedish).
2. Solderer, A., et al., Efficacy of chlorhexidine rinses after periodontal or implant surgery: a systematic review. *Clin Oral Investig*, 2019;23(1):21-32.
3. Wyatt CCL, MacEntee MI. Caries management for institutionalized elders using fluoride and chlorhexidine mouthrinses. *Community Dent Oral Epidemiol*, 2004;32:322-328.

Medel för lokal behandling av munslemhinneförändringar

1. Fridh G, Koch G. Effect of a mouth rinse containing amyloglucosidase and glucose oxidase on recurrent aphthous ulcers in children and adolescents. *Swed Dent J.* 1999;23(2-3):49-57
2. Henricsson V, Axéll T. Treatment of recurrent aphthous ulcers with Aureomycin mouth rinse or Zendium dentifrice. *Acta Odontol Scand.* 1985 Mar;43(1):47-52
3. Lodi G, Manfredi M, Mercadante V, Murphy R, Carrozzo M. Interventions for treating oral lichen planus: corticosteroid therapies. *Cochrane Database of Systematic Reviews* 2020, Issue 2. Art. No.: CD001168. DOI: 10.1002/ 14651858.CD001168.pub3.
4. Lo Muzio L, della Valle A, Mignogna MD, Pannone G, Bucci P, Bucci E, Sciubba J. The treatment of oral aphthous ulceration or erosive lichen planus with topical clobetasol propionate in three preparations: a clinical and pilot study on 54 patients. *J Oral Pathol Med* 2001 Nov;30(10):611-7.
5. Nolan A, Baillie C, Badminton J, Rudralingham M, Seymour RA. The efficacy of topical hyaluronic acid in the management of recurrent aphthous ulceration. *J Oral Pathol Med* 2006 Sep;35(8):461-5.
6. Porter SR, Al-Johani K, Fedele S, Moles DR. Randomised controlled trial of the efficacy of HybenX in the symptomatic treatment of recurrent aphthous stomatitis. *Oral Dis.* 2009 Mar;15(2):155-61
7. Porter S, Scully C. Aphthous ulcers: recurrent. *Clin Evid.* 2005 Jun;(13):1687-94.

Medel för lokal smärtlindring

1. Epstein JB, et al. Benzydamine HCL for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. *Cancer.* 2001;92:875-85.

Medel vid svampinfektion

1. Goins RA, Ascher D, Waecker N, Arnold J, Moorefield E. Comparison of fluconazole and nystatin oral suspensions for treatment of oral candidiasis in infants. *Pediatr Infect Dis J.* 2002;21:1165-7.
2. Taillandier J, Esnault Y, Alemanni M. A comparison of fluconazole oral suspension and amphotericin B oral suspension in older patients with oropharyngeal candidosis. Multicentre Study Group. *Age Ageing.* 2000;29:117-23.
3. Stafford GD, Arendorf T, Huggett R. The effect of overnight drying and water immersion on candidal colonization and properties of complete dentures. *J Dent.* 1986;14:52-6.

Medel för premedicinering

1. Ashley, P.F., M. Chaudhary, and L. Lourenco-Matharu, Sedation of children undergoing dental treatment. *Cochrane Database Syst Rev,* 2018;12:CD003877.
2. Erlandsson AL, et al. Conscious sedation by oral administration of midazolam in paediatric dental treatment. *Swed Dent J,* 2001;25:97-104.
3. Lindh-Stromberg U. Rectal administration of midazolam for conscious sedation of uncooperative children in need of dental treatment. *Swed Dent J,* 2001;25:105-11.
4. Eriksson L, Rune J. Dosering av midazolam per os i käkkirurgisk praxis. *Tandläkartidningen,* 2001;93:40-42.
5. Melini, M., et al., Conscious sedation for the management of dental anxiety in third molar extraction surgery: a systematic review. *BMC Oral Health,* 2020;20(1):155.

Medel vid bakteriell infektion

1. Antibiotikaprofylax för att förebygga endokardit i samband med odontologiska ingrepp. Tandläkartidningen 2016;4:68.
2. Läkemedelsverket. Indikationer för antibiotikaprofylax i tandvården – ny rekommendation. Information från Läkemedelsverket 2012;5:22-35. <https://www.lakemedelsverket.se>
3. Läkemedelsverket. Rekommendationer för antibiotikabehandling i tandvården. Information från Läkemedelsverket 2014;1:19-30. <https://www.lakemedelsverket.se>
4. National Institute for Health and Care Excellence (NICE). Prophylaxis against infective endocarditis: Antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures. Issued: March 2008 last modified: September 2015. NICE clinical guideline 64. <https://www.nice.org.uk>
5. Rekommendation för antibiotika till patienter som strålbehandlats mot munhålan. Tandläkartidningen 2016;5:58-59.
6. Socialstyrelsen. National Guidelines for Adult Dental Care 2011. <https://www.socialstyrelsen.se/en/regulations-and-guidelines/national-guidelines/> (21 november 2016)
7. 2015 ESC Guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC). Eur Heart J. 2015;36(44):3075–128.

Medel vid blödningskomplikation

1. Bacci C et al. Management of dental extraction in patients undergoing anticoagulant treatment. Results from a large multicentre, prospective, case-control study. Thromb Haemost 2010 nov;104(5):972-5.
2. Manfredi M, Dave B, Percudani D, Christoforou J, Karasneh J, Diz Dios P, Glick M, Kumar N, Lockhart PB, Patton LL World workshop on oral medicine VII: Direct anticoagulant agents management for invasive oral procedures: A systematic review and meta-analysis. Oral Dis. 2019 Jun;25 Suppl 1:157-173.
3. Yoshikawa H, Yoshida M, Yasaka M, Yoshida H, Murasato Y, Fukunaga D, Shintani A, Okada Y. Safety of tooth extraction in patients receiving direct oral anticoagulant treatment versus warfarin: a prospective observation study. Int J Oral Maxillofac Surg. 2019 Feb 48:1102-1108.

Särskilt tandvårdsbidrag

1. Särskilt tandvårdsbidrag – föreskrifter, Socialstyrelsen, 2012, <https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/foreskrifter-och-allmanna-rad/2012-12-11.pdf>

Läkemedelsrelaterad käkbensnekros, MRONJ (Medication-Related Osteonecrosis of the Jaws)

1. Workshop of European Task Force on Medication Related Osteonecrosis of the Jaw. Current challenges. Schiodt M, Otto S, Fedele S, Bedogni A, Nicolatou-Galitis O, Guggenberger R, et al. Oral Dis. 2019 Oct;25(7):1815-1821.
2. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56.
3. Larsson Wexell C, Brokstad Herlofson B, Norholt SE, Cardemil C, Schiodt M. Läkemedelsrelaterad osteonekros i käkarna, del 1. Tandläkartidningen 2015, 12.
4. Läkemedelsverket. Indikationer för antibiotikaprofylax i tandvården – ny rekommendation. Information från Läkemedelsverket 2012;5:22-35. <https://www.lakemedelsverket.se>

Referenser Neurologi

Epilepsi

- Cochrane metaanalys December 2017 <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011412.pub3/full>
- Glauser et al, *Epilepsia* 2006 jul; 47(7): 1094-120: ILAE Treatment Guidelines: Evidence-based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes
- Helmstaedter C, Witt JA. *Epilepsy Behav.* 2010 May;18(1-2):74-80: Cognitive outcome of antiepileptic treatment with levetiracetam versus carbamazepine monotherapy: a non-interventional surveillance trial.
- Läkemedelsverkets behandlingsrekommendationer, epilepsi. 2019
- <https://lakemedelsverket.se/malgrupp/Halso---sjukvard/Behandlings--rekommendationer/Behandlingsrekommendation--listan/Epilepsi/>
- Marson et al, *Lancet* 2007 Mar 24; 369: 1000-1026: The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.
- Marson AG, Kadir ZA, Hutton JL, Chadwick DW. *Epilepsia.* 1997 Aug;38(8):859-80: The new antiepileptic drugs: a systematic review of their efficacy and tolerability.
- Marson AG, Hutton JL, Leach JP, Castillo S, Schmidt D, White S, Chaisewikul R, Privitera M, Chadwick DW. *Epilepsy Res.* 2001 Sep;46(3):259-70: Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review.
- Meador KJ, Gevins A, Loring DW, McEvoy LK, Ray PG, Smith ME, Motamedi GK, Evans BM, Baum C. *Neurology.* 2007 Nov 27;69(22):2076-84: Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam.

Migrän och spänningshuvudvärk

1. <https://huvudvarkssallskapet.se/huvudvarksdagbok/>
 2. <https://vardgivare.skane.se/vardriktlinjer/lakemedel>
- Aurora et al, *Cephalalgia.* 2010 Jul;30(7):793-803. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
 - Cochrane Database of Systematic Reviews Acupuncture for the prevention of episodic migraine, 2016
 - <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001218.pub3/epdf/full>
 - Diener et al, *Cephalalgia.* 2010 Jul;30(7):804-14. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.
 - Jackson et al, *PLoS One.* 2019 Mar 20;14(3):e0212785 Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis.
 - Jackson et al, *J Gen Intern Med.* 2017 Dec;32(12):1351-1358. Tricyclic and Tetracyclic Antidepressants for the Prevention of Frequent Episodic or Chronic Tension-Type Headache in Adults: A Systematic Review and Meta-Analysis.
 - Jackson et al, *PLoS One.* 2015 Jul 14;10(7):e0130733. A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache.
 - Janusinfo – graviditet och triptaner, <https://janusmed.sll.se/#/home/fosterpaverkan>
 - Källén et al, *Drug Saf.* 2011 vol. 34(8) pp. 691-703 Delivery outcome after maternal use of drugs for migraine: a register study in Sweden
 - Liampas et al, Findings of systematic review and meta-analysis suggest potential benefit of melatonin in the prevention of migraine in adults Headache 2020 Apr 30
 - Nezvalová-Henriksen et al, *Eur. J. Epidemiol.*, 2013 vol. 28(9) pp. 759-69 Triptan safety during pregnancy: a Norwegian population registry study
 - Stovner et al. *Cephalalgia* 2013; 34: 523–32. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study.
 - Tepper et al, *Lancet Neurol.* 2017 Jun;16(6):425-434. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
 - Silberstein et al, *N Engl J Med.* 2017 Nov 30;377(22):2113-2122. Fremanezumab for the Preventive Treatment of Chronic Migraine.
 - NT-rekommendation Aimovig och Ajovy <https://janusinfo.se/download/18.6099bd3a174afc870ff64e8d/1603701621525/Emgality-Aimovig-Ajovy-200925.pdf>

Parkinsons sjukdom

- Läkemedelsverkets behandlingsrekommendationer vid Parkinsonism, 2008
- <https://lakemedelsverket.se/malgrupp/Halso---sjukvard/Behandlings--rekommendationer/Behandlingsrekommendation---listan/Parkinsonism/>
- PD MED Collaborative Group, Lancet. 2014 Sep 27;384 (9949):1196-205 Long-term effectiveness of dopamine ago-nists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.

Sekundärprofylax efter stroke/TIA

- Adam et al, Ann Intern Med 2012 Aug 28, Epub ahead of print, Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic Re-view.
- Benavente et al, Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367:817–825.
- Boulouis et al, J Neurol Neurosurg Psychiatry. 2017 Oct 13. pii: jnnp-2017-316631. Outcome of intracerebral haemorrhage related to non-vitamin K antagonists oral anticoagulants versus vitamin K antagonists: a comprehensive systematic review and meta-analysis.
- Camm et al, Eur Heart J. 2012 Aug 24, 2012 focused update of the ESC Guidelines for the management of atrial fibrillation
- Connolly et al, N Engl J Med 2009 Sep 17;361(12):1139-51, Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY trial).
- Connolly et al, N Engl J Med. 2011 Mar 3;364(9):806-17. Apixaban in patients with atrial fibrillation. (AVERROES)
- Connolly et al, N Engl J Med. 2019 Apr 4;380(14):1326-1335. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. (ANNEXA-4)
- CURRENT– OASIS 7 Investigators, N Engl J Med 2010;363:930-42. Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes
- Diener et al, J Neurol Sci 1996;143:1-13, Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke (ESPS2)
- Diener et al, Lancet, 364 (2004), pp. 331–337, Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients randomized, double-blind, placebo-controlled trial (MATCH)
- Diener et al, N Engl J Med. 2019 May 16;380(20):1906-1917. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. (RE-SPECT ESUS)
- Diener et al, Lancet Neurol 2010; 9: 1157–63, Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial
- Halkes et al, ESPRIT Study Group, Lancet 2006;367:1665–1673, Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin: a randomised controlled trial (ESPRIT).
- Friberg et al, Open Heart 2017;4:e000682. doi:10.1136/openhrt-2017-000682 Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation
- Gorelick et al, Stroke Research and Treatment, Volume 2013, Article ID 727842 Review Article: Advances in Our Understanding of “Resistance” to Antiplatelet Agents for Prevention of Ischemic Stroke
- Granger et al, N Engl J Med 2011 Sep 15;365(11):981-92, Apixaban versus Warfarin in Patients with Atrial Fibrillation (ARISTOTLE trial)
- Guigliano et al, N Engl J Med 2013 Nov 28;369(22):2093-104, Edoxaban versus warfarin in patients with atrial fibrillation (ENGAGE AF-TIMI 48 trial)
- Halvorsen et al, Eur Heart J Cardiovasc Pharmacother. 2017 Jan;3(1):28-36. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
- Hart et al, N Engl J Med. 2018 Jun 7;378(23):2191-2201, Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source (NAVIGATE-ESUS trial)
- Huang et al, JAMA Neurol. 2018 Dec 1;75(12):1511-1518. Association of Intracranial Hemorrhage Risk With Non-Vitamin K Antagonist Oral Anticoagulant Use vs Aspirin Use: A Systematic Review and Meta-analysis.
- Huhtakangas et al, Int J Stroke. 2015 Aug;10(6):876-81, Improved survival of patients with warfarin - associated intracerebral haemorrhage: a retrospective longitudinal population-based study
- Johnston et al, N Engl J Med. 2016 Jul 7;375(1):35-43, Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack (SOCRATES trial)
- Johnston et al, N Engl J Med. 2018 Jul 19;379(3):215-225, Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA (POINT trial)
- Kermer et al, Int J Stroke. 2017 Jun;12(4):383-391, Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A national case collection.

- Kim et al, Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis, *Stroke* 2019 Dec;50(12):3503-3511
- Lee et al, *Stroke* 2017;48:2610–2613 Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin, A Systematic Review and Meta-Analysis
- Liu et al, <https://link.springer.com/journal/10557> Cardiovascular Drugs and Therapy volume 34, pages569–578(2020)
- Läkemedelsverket, Information från läkemedelsverket 1:2017 Antikoagulantibehandling vid förmaksflimmer – behandlingsrekommendation <https://www.lakemedelsverket.se/sv/behandling-och-forskrivning/behandlingsrekommendationer/sok-behandlingsrekommendationer/antikoagulantibehandling-vid-formaksflimmer>
- Ntaois et al, *Stroke*. 2017;48:2494-2503 Real-World Setting Comparison of Nonvitamin-K Antagonist
- Olesen et al, *Thrombosis and Hemostasis* 2011: 106: 739-749 Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study.
- Parry-Jones et al, *Ann Neurol*. 2015 Jul;78(1):54-62, Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage.
- Patel et al, *N Engl J Med* 2011;365:883-91, Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation (ROCKET-AF trial)
- Pink et al, *BMJ* 2011, Oct 31; 343, Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses
- Pollack et al, *N Engl J Med*. 2017 Aug 3;377(5):431-441, Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. (RE-VERSE AD)
- Reddy et al, *J Am Coll Cardiol*. 2017 Nov 4. pii: S0735-1097(17)41187-9, 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.
- Rothwell et al, *Lancet*. 2007 Oct 20;370(9596):1432-42, Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison.
- Sacco et al, *N Engl J Med* 2008 Sep 18;359(12):1238-51. Epub 2008 Aug 27, Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke (PROFESS trial).
- Saxena et al, *The Cochrane Library* 2008, Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack
- Schulz, *Maturitas*. 2013 Nov;76(3):267-71. Drug treatments in the secondary prevention of ischaemic stroke.
- Siegal et al, *N Engl J Med*. 2015 Dec 17;373(25):2413-24. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
- Själander et al, *Thromb Res*. 2018 Jul;167:113-118. Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation.
- Socialstyrelsen, Nationella riktlinjer för vård vid stroke 2018 <https://www.socialstyrelsen.se/regler-och-riktlinjer/nationella-riktlinjer/slutliga-riktlinjer/stroke/>
- Staerk et al, *J Intern Med*. 2018 Jan;283(1):45-55. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study.
- Steiner et al, *Lancet Neurol*. 2016 May;15(6):566-73. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial.
- Wallentin et al, *Lancet* 2010: 376: 975-83: Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
- Wang et al, *N Engl J Med* 2013;369:11-19. Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE)
- Webb, A.J., et al., Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. *Lancet*, 2010. 375(9718): p. 906-15.
- Wright et al, *N Engl J Med*. 2015 Nov 26;373(22):2103-16. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

RLS

- Anguelova, G.V., et al., Pharmacologic and Nonpharmacologic Treatment of Restless Legs Syndrome. *Sleep Med Clin*, 2018. 13(2): p. 219-230.
- Aurora, R.N., et al., The treatment of restless legs syndrome and periodic limb movement disorder in adults-an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. *Sleep*, 2012. 35(8): p. 1039-62.
- Burman D. Sleep Disorders: Restless Legs Syndrome. *FP Essent [Internet]*. 2017 Sep [cited 2018 Jul 15];460:29–32. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/28845959>

- Garcia-Borreguero D, Cano-Pumarega I, Marulanda R. Management of treatment failure in restless legs syndrome (Willis-Ekbom disease). *Sleep Med Rev* [Internet]. 2018 Jan 9 [cited 2018 Jul 15]; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29602660>
- Garcia-Borreguero, D., et al., European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. *Eur J Neurol*, 2012. 19(11): p. 1385-96.
- Garcia-Borreguero, D., et al., The long-term treatment of restless legs syndrome/ Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. *Sleep Med*, 2013. 14(7): p. 675-84.
- Ghorayeb, I., Idiopathic restless legs syndrome treatment: Progress and pitfalls? *Adv Pharmacol*, 2019. 84: p. 207-235.
- Romenets, S.R. and R.B. Postuma, Treatment of Restless Legs Syndrome. *Current Treatment Options in Neurology*, 2013(DOI 10.1007/s11940-013-0241-x).
- Tipton PW, Wszolek ZK. Restless legs syndrome and nocturnal leg cramps: review and guide to diagnosis and treatment. *Polish Arch Intern Med* [Internet]. 2017 Nov 9 [cited 2018 Jul 15];127(12):865–72. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29120993>
- Trenkwalder, C., et al., Comorbidities, treatment, and pathophysiology in restless legs syndrome. *Lancet Neurol*, 2018, 17(11): p. 994-1005.
- Trenkwalder, C. and W. Paulus, Pharmacological treatments of augmentation in restless legs syndrome patients. *Adv Pharmacol*, 2019. 84: p. 255-265.
- Wijemanne S, Ondo W. Restless Legs Syndrome: clinical features, diagnosis and a practical approach to management. *Pract Neurol* [Internet]. 2017 Dec [cited 2018 Jul 15];17(6):444–52. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29097554>
- Winkelmann J, Allen RP, Högl B, Inoue Y, Oertel W, Salminen A V., et al Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017) *S. Mov Disord* [Internet]. 2018 May 14 [cited 2018 Jul 15]; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29756335>

Referenser Osteoporos

- TA087 Osteoporosis – secondary prevention – NICE Guidance. January 2005. <http://www.nice.org.uk>. Accessed 3rd January 2005.
- Nationella riktlinjer för rörelseorganens sjukdomar 2012. Osteoporos, artros, inflammatorisk ryggsjukdom och ankyloserande spondylit, psoriasisartrit och reumatoid artrit. Socialstyrelsen 2012. ISBN: 978-91-87169-32-8.
- Ernst E et al. Exercise for female osteoporosis. A systematic review of randomised clinical trials. *Sports med* 1998;25:359-68.

Epidemiologi och diagnos

- Evaluation of decision rules for referring women for bone densitometry by dual x-ray absorptiometry. *JAMA* 2001;286:57-62
- Cummings et al. Bone density at various sites for prediction of hip fractures. *Lancet* 1993;341:72-5.
- Garnero et al. Markers of bone turnover for the prediction of fracture risk. *Osteoporosis Int* 2000;11:55-56.
- Kanis JA, Johnell O, Oden et al. Ten year probabilities of osteoporotic fracture according to BMD and diagnostic threshold. *Osteoporosis Int.* 2001;12:989-95.
- Kanis JA, Johnell O, Oden et al. FRAX and the assessment of fracture probability in men and women from the UK. *Osteop Int.* 2008 Apr;19(4):385-97.
- Law et al. A meta-analysis of smoking, bone mineral density and risk of hip fracture: recognition of a major effect. *BMJ* 1997;315:841-6.
- Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. *BMJ* 1996;312:1254-1259.
- Versluis RG, Papapoulos SE, de Bock GH et al. Clinical risk factors as predictors of how well measures of bone density predict occurrence of osteoporosis in general practice. *BJGP* 2001;51:806-10
- Watts NB. The fracture risk assessment tool (FRAX): applications in clinical practice. *J Womens health (Larchmt)*. 2011 Apr;20(4):525-31.
- Huntjens K, van Geel T, van den Bergh J et al. Fracture Liaison Service: Impact on subsequent nonvertebral fracture incidence and mortality. *J Bone Joint Surg Am.* 2014; 96:e29(1-8).

Behandling

- Adler R, Ghada El-Hajj F, Bauer D et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American society for bone and mineral research. *JBMR* 2016 Jan. Vol 31, no 1, 16-35.
- Cranney A, Guyatt G, Griffith L, et al; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. *Endocr Rev.* 2002 Aug;23(4):570-8.
- Devogelaer JP, Goemare S, Boonen S, et al. Evidence-based guidelines for the prevention and treatment of glucocortico-idinduced osteoporosis: a consensus document of the Belgian Bone Club. *Osteop Int.* 2006 Jan;17(1):8-19.
- Hauselmann HJ, Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis. *Osteop Int* 2003;14:2-12.
- McClung M, Harris S et al. Bisphosphonate therapy for osteoporosis; benefits, risks and drug holiday. *Am J Med.* 2013 Jan;126(1):13-20.
- Reginster J. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. *Drugs* 2011;71(1); 65-78.
- Saito T, Sterbenz J.M. Malam S et al. Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis. *Osteop Int* 2017; 28; 3289-3300.

Bisfosfonater

- McClung et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group. *NEJM* 2001;344:333-40
- Devogelaer JP et al. Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. *Osteoporosis Int.* 2007;18(9):1211-8.
- Liu H, Michaud K, Nayak S, et al. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. *Arch Intern Med.* 2006;166(11):1209-17.
- Black DM, Delmas PD, Eastell R, et al; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. *N Engl J Med.* 2007;356(18):1809-22.

- Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. *N Engl J Med*. 2007;357(18):1799-809.
- Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. *Cochrane Database Syst Rev*. 2008 Jan 23;(1):CD004523. Review.
- Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. *Cochrane Database Syst Rev*. 2008 Jan 23;(1):CD001155. Review.
- Schilcher J, Michaëlsson K, Aspenberg P; Bisphosphonate use and atypical fractures of the femoral shaft. *N Engl J Med* 2001;362:1728-37.

Raloxifen

- Cranney A, Tugwell P, Zytaruk N, et al. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. *Endocr Rev*. 2002 Aug;23(4):524-8. Review.

PTH

- Cranney A, Papaioannou A, Zytaruk N, et al; Clinical Guidelines Committee of Osteoporosis Canada. Parathyroid hormone for the treatment of osteoporosis: a systematic review. *CMAJ*. 2006;175(1):52-9. Review.
- Greenspan SL, Bone HG, Ettinger MP, et al; Treatment of Osteoporosis with Parathyroid Hormone Study Group. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. *Ann Intern Med*. 2007;146(5):326-39. Summary for patients in: *Ann Intern Med*. 2007;146(5):i20.

Denosumab

- McClung MR, Lewiecki EM, Cohen SB et al. AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. *N Engl J Med*. 2006;354(8):821-31.
- Cummings SR, San Martin J, McClung MR et al. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. *N Engl J Med*. 2009;361(8):756-65. Erratum in: *N Engl J Med*. 2009 Nov 5;361(19):1914.
- Smith MR, Egerdie B, Hernández Toriz N et al. Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. *N Engl J Med*. 2009;361(8):745-55.
- Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. *J Clin Oncol*. 2010;28(35):5132-9.
- Miller PD, Wagman RB, Peacock M et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. *J Clin Endocrinol Metab* 2011 Feb;96(2):394-402.

Vitamin D

- Lorentzon M, Åkesson K, Mellström D et al. D-vitaminbehandling och skeletthälsa – svenska riktlinjer behövs. Rekommendationer från svenska osteoporossällskapets kliniska expertgrupp. *Läkartidningen*. 2014;111;CW6C:1-4.
- Maier S, Sidelnikov E, Dawson-Hughes B et al. Before and after hip fracture, vitamin D deficiency may not be treated sufficiently. *Osteoporos Int* 2013;24:2765-73.
- Cranney A, Weiler HA, O'Donnell S, Pui L. Summary of evidence-based review on vitamin D efficacy and safety in relation to bone health. *Am J Clin Nutr*. 2008 Aug;88(2):513S-519S. Review.
- Avenell A, Mak JCS, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men (Review) *Cochrane Database of Systematic Reviews* 2014, Issue 4.

Referenser Psykiatri

- Allgulander, C et al: Nytt och risker med bensodiazepiner. Aktuell faktaanlys, Läkartidningen 2011 nr 41 sid 2025-9; <http://www.lakartidningen.se/>
- Behandling av alkoholabstinens - en uppdatering av evidensläget efter SBU-rapporten, 2010. https://lakemedelsverket.se/upload/halso-och-sjukvard/behandlingsrekommendationer/bakg_dok/Bakgrund_alkoholabstinens_bokm%C3%A4rken.pdf
- Behandling av alkohol- och narkotikaproblem, SBU-rapport nr 156 (2 volymer) 2001; <http://www.sbu.se/sv/publikationer/SBU-utvarderar/behandling-av-alkohol-och-narkotikaproblem/>
- Läkemedelsbehandling vid alkoholberoende (Läkemedelsverket 2007;18 (1)); https://lakemedelsboken.se/kapitel/beroendetilstand/alkohol-riskbruk_missbruk_och_beroende.html
- National Institute of Clinical Excellence: Clinical Guidelines CG115 Issued Feb 2011, Alcohol Use Disorders: diagnosis, assessment and management av harmful drinking and alcohol dependence; <https://www.nice.org.uk/guidance/cg115>
- Nationella riktlinjer för vård och stöd vid missbruk och beroende – Stöd för styrning och ledning; <https://www.socialstyrelsen.se/regler-och-riktlinjer/nationella-riktlinjer/slutliga-riktlinjer/missbruk-och-beroende/>
- Practice Guideline for The Treatment of Patients With Substance Use Disorders, Second Edition, American Psychiatric Association https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/substanceuse.pdf
- Socialstyrelsens föreskrifter och allmänna råd om läkemedelsassisterad underhållsbehandling vid opiatberoende (SOSFS 2011:9); <https://www.socialstyrelsen.se/regler-och-riktlinjer/nationella-riktlinjer/slutliga-riktlinjer/missbruk-och-beroende/>
- 2011-11-22: SBU-rapporter ang behandling med naltrexon och akamprosot vid alkoholberoende: <https://www.sbu.se/sv/publikationer/sbu-kommentar/behandling-med-akamprosot-vid-alkoholberoende/>, <http://www.sbu.se/sv/publikationer/sbu-kommentar/behandling-med-naltrexon-vid-alkoholberoende/>
- Tema Riskbruk, Missbruk, Beroende, Läkartidningen nr 45 2011 volym 108, pp 2279- 2315; <http://www.lakartidningen.se/Functions/OldArticleView.aspx?articleId=17273>
- Pharmacotherapy for alcohol dependence: status of current treatment Johan Franck and Nitya Jayaram-Lindström 2013, <http://www.science-direct.com/science/article/pii/S0959438813001190>

Beroende:

- (1) <https://vardgivare.skane.se/vardriktlinjer/lakemedel/#43054>
- (2) <https://www.socialstyrelsen.se/utveckla-verksamhet/evidensbaserad-praktik/metodguiden/audit-alkohol-use-disorders-identification-test/>
- (3) <https://www.socialstyrelsen.se/utveckla-verksamhet/evidensbaserad-praktik/metodguiden/dudit-drug-use-disorders-identification-test/>
- Uhl GR, Drgon T, Johnson C, Fatusin OO, Liu QR, Contoreggi C, et al. »Higher order« addiction molecular genetics: Convergent data from genome-wide association in humans and mice. *Biochem Pharmacol.* 2008;75:98-111.
- Ishiguro H, Gong JP, Hall FS, Arinami T, Uhl GR. Association of PTPRB gene polymorphism with drug addiction. *Am J Med Genet B Neuropsychiatr Genet.* 2008;147B(7):1167-72.
- Le Moal M, Koob GF. Drug addiction: pathways to the disease and pathophysiological perspectives. *Eur Neuropsychopharmacol.* 2007;17:377-93.
- Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: The role of reward-related learning and memory. *Annu Rev Neurosci.* 2006;29:565-98. Bokkapitlet om beroendets biologi
- (Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. *Pain Physician.* 2012;15:ES67-92.)
- Rang and Dale
- Mclean J, Manchip S. Wernicke's encephalopathy induced by magnesium depletion. *The Lancet.* Volume 353, Issue 9166, 22 May 1999, Page 1768. <https://www.sciencedirect.com/science/article/pii/S0140673699001828?via%3Dihub#!>
- Sudakin D. Naltrexone: Not Just for Opioids Anymore. *J Med Toxicol.* 2016 Mar; 12(1): 71–75. Published online 2015 Nov 6. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4781804/>
- Kalk N J, Lingford-Hughes A R. The clinical pharmacology of acamprosate. *Br J Clin Pharmacol.* 2014 Feb; 77(2): 315–323. Published online 2014 Jan 22. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014018/>
- <https://www.socialstyrelsen.se/regler-och-riktlinjer/nationella-riktlinjer/slutliga-riktlinjer/missbruk-och-beroende/>

För överdosedepidemin:

- <https://www.cdc.gov/opioids/strategy.html>

Referenser för prevalens

- <https://www.folkhalsoguiden.se/>

Bipolära syndrom:

- (Merikangas et al., 2007 Merikangas KR, Akiskal HS, Angst J, et al. (2007) Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch Gen Psychiatry 64:543–552.).
- (Barnett och Smoller, 2009 Barnett JH, Smoller JW (2009) The genetics of bipolar disorder. Neuroscience, 164:331-343 och SPF)
- Svenska psykiatriska föreningen (SPF) <http://www.svenskpsykiatri.se/>
- Affektiva symptom är dödliga – självmordsrisken är hög <http://www.lakartidningen.se/Functions/OldArticleView.aspx?articleId=19316>
- SBU <http://www.sbu.se/sv/sok/?q=bipol%C3%A4r+sjukdom>
- Läkemedelsverket Behandlingsrekommendationen om depression, ångest och tvångssyndrom
- <https://lakemedelsverket.se/malgrupp/Halso---sjukvard/Behandlings--rekommendationer/Behandlingsrekommendation---listan/Depression-angestsyndrom-och-tvangssyndrom-hos-barn-och-vuxna/>
- Olanzapine/Fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial. [http://www.jaacap.com/article/S0890-8567\(14\)00891-0/fulltext](http://www.jaacap.com/article/S0890-8567(14)00891-0/fulltext)
- Lithium in the acute treatment of bipolar I disorder: a double-blind placebo-controlled study
- <http://pediatrics.aappublications.org/content/early/2015/10/06/peds.2015-0743>
- A consecutive series of treated affected offspring of parents with bipolar disorder: is response associated with the clinical problem <http://journals.sagepub.com/doi/abs/10.1177/070674370705200606>
- S3-Leitlinie zur Diagnostik und Therapie Störungen <https://link.springer.com/article/10.1007/s00115-011-3415-3>
- Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. <http://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.161.2.217>
- A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I) <http://www.psychiatrist.com/JCP/article/Pages/2010/v71n02/v71n0206.aspx>
- Effects of chronic lithium treatment on renal function <http://www.sciencedirect.com/science/article/pii/S016503271000354X>
- Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry <http://www.sciencedirect.com/science/article/pii/S016503271000354X>
- Principles of antiepileptic drug action https://books.google.se/books?id=HAOY0qG-vAYC&pg=PA3&lpg=PA3&dq=Principles+of+antiepileptic+drug+action%22.&source=bl&ots=xJ-GOWRdhHj&sig=EqsFobX0qyPS3Jetzxn1mCCGw04&hl=sv&sa=X&ved=0ahUKEwjYo_WljaXWAhWIF5oKHbwqC-sQ6AEIMzAB#v=onepage&q=Principles%20of%20antiepileptic%20drug%20action%22.&f=false
- Risperidone long-acting injectable (Risperdal Consta(R)) for maintenance treatment in patients with bipolar disorder <https://www.ncbi.nlm.nih.gov/pubmed/20977322>
- Depot antipsychotic medications in bipolar disorder: a review of the literature https://www.researchgate.net/publication/6152047_Depot_antipsychotic_medications_in_bipolar_disorder_A_review_of_the_literature?ev=publicSearchHeader&_sg=ELzCjPIV18FFeBMYUtnzPv0Xway3mJ-QEZBgT5A34B12ecqUi5Z8SncBohO7EW_x2WdCwxKQImP2qzDI
- Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration <http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0447.2008.01237.x/full>

Depression:

- (4) <https://ki.se/nasp/sjalvmord-i-sverige>
- (5) <https://www.socialstyrelsen.se/regler-och-riktlinjer/nationella-riktlinjer/publicerade-riktlinjer/depression-och-angest/>
- (6) [https://janusinfo.se/download/18.4f6bed70172c02901d0e9fd2/1593087696372/Esketamin-\(Spravato\)-200625.pdf](https://janusinfo.se/download/18.4f6bed70172c02901d0e9fd2/1593087696372/Esketamin-(Spravato)-200625.pdf)
- Behandling av depressionssjukdomar, SBU-rapport nr 166 (2 volymer) 2004; <https://www.sbu.se/sv/publikationer/SBU-utvarderar/behandling-av-depressionssjukdomar/>

- Bergen H et al: A comparative study of non-fatal self-poisoning with antidepressants relative to prescribing in three centres in England; *J Affect Disord.* 2010 Jun;123(1-3):95-101. Epub 2009 Oct 28; <http://www.sciencedirect.com/science/article/pii/S0165032709004649>
- Combining Medications to Enhance Depression Outcomes (CO-MED Study): <https://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.2011.10111645>
- European Medicines Agency (EMA): Pharmacovigilance Working Party (PhVWP), 27 October 2011 http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/10/WC500117061.pdf (citalopram)
- European Medicines Agency (EMA): Pharmacovigilance Working Party (PhVWP), 24 November 2011; http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/11/WC500117988.pdf (escitalopram)
- H. Lundbeck AB; (s k "Dear Doctor"-letter till hälsovårdspersonal, Cipramil och Citalopram CNSPharma (citalopram hydrobromid) associerade med dosberoende förlängning av QT-intervall; personligt informationsbrev till alla svenska förskrivare daterat den 26 oktober 2011 undertecknat av Sofia Lagerholm, Regulatory Affairs Manager, H. Lundbeck AB
- H. Lundbeck AB; (s k "Dear Doctor"-letter till hälsovårdspersonal, Escitalopram (Cipralex) associerat med dosberoende förlängning av QT-intervall; personligt informationsbrev till alla svenska förskrivare daterat den 5 december 2011 undertecknat av Anders Luts, Medicinsk Chef, H. Lundbeck AB, Sverige
- Howell C, Wilson A D, Waring W S: Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases, *Br J Clin Pharmacol.* 2007 Aug;64(2):192-7. Epub 2007 Feb 12; <http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2007.02849.x/full>
- Depression, ångestsyndrom och tvångssyndrom hos barn och vuxna 2016; <https://lakemedelsverket.se/malgrupp/Halso--sjukvard/Behandlings-rekommendationer/Behandlingsrekommendation--listan/Depression-angestsyndrom-och-tvangssyndrom-hos-barn-och-vuxna/>
- Farmakologisk depressionsbehandling i primärvården – några typfall, poster utformad av Terapigrupp Psykiatri Region Skåne december 2011; <https://vardgivare.skane.se/kompetens-utveckling/sakkunniggrupper/terapigrupper/>
- Hayes BD: Comparison of toxicity of acute overdoses with citalopram and escitalopram; *J Emerg Med* 2010 Jul;39(1):44-8. Epub 2008 Dec 11; <http://www.sciencedirect.com/science/article/pii/S0736467908006677>
- Hawton K et al: Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose, *Br J Psychiatry.* 2010 May;196(5):354-8; <http://bjp.rcpsych.org/content/196/5/354>
- Kelly C A et al: Comparative toxicity of citalopram and the newer antidepressants after overdose, *J Toxicol Clin Toxicol.* 2004;42(1):67-71; <http://www.tandfonline.com/doi/abs/10.1081/CLT-120028747>
- Läkemedelsverket: Citalopram – sänkt maxdos rekommenderas, 27 oktober 2011; <https://lakemedelsverket.se/Alla-nyheter/NYHETER-2011/Citalopram--sankt-maxdos-rekommenderas/>
- Läkemedelsverket: Escitalopram – sänkt maxdos för äldre rekommenderas, 27 november 2011 <https://lakemedelsverket.se/Alla-nyheter/NYHETER-2011/Escitalopram--sankt-maxdos-for-aldre-rekommenderas/>
- Mohammed R et al: Prolonged QTc interval due to escitalopram overdose; *J Miss State Med Assoc.* 2010 Dec;51(12):350-3; <https://www.ncbi.nlm.nih.gov/pubmed/21370605>
- National Institute Of Clinical Excellence (NICE guidelines issued October 2009) CG90 Depression: Depression: the treatment and management of depression in adults (update); <https://www.nice.org.uk/guidance/CG90>
- Odar-Cederlöf I et al: Citalopram inte riskfritt från hjärtsynpunkt. SSRI-preparat kan ge förlängd QTc-tid *Läkartidningen* 2006 nr 14 sid 1112-4; <http://lakartidningen.se/>
- Personne M et al: Toxicitet vid överdosering av nya antidepressiva. Genomgång av epikrismaterial visar olika svår symtombild för olika medel *Läkartidningen* 2008 nr 3 sid 125-7; http://www.lakartidningen.se/store/articlepdf/8/8558/LKT0803s125_127.pdf
- Practice Guideline for The Treatment of Patients With Major Depressive Disorders , American Psychiatric Association November 2010; https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
- (7) Rush AJ et al: Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report, *Am J of Psychiatry,* Nov 2006; 163; 1905-1917; <http://ajp.psychiatryonline.org/doi/pdf/10.1176/ajp.2006.163.11.1905>
- (7) Rush AJ : STAR*D: What Have We Learned?, *Am J Psychiatry,* Feb 2007; 164: 201 – 204; <http://ajp.psychiatryonline.org/doi/pdf/10.1176/ajp.2007.164.2.201>
- Rush AJ et al: Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study; *Am J of Psychiatry,* July 2011; 168; 689-701; <http://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.2011.10111645>
- SBU: Diagnostik och uppföljning av förstämningssyndrom (20121107); <https://www.sbu.se/sv/publikationer/skrifter-och-faktablad/diagnostik-av-forstamningssyndrom/>
- Socialstyrelsen: Nationella riktlinjer för depressionssjukdom och ångestsyndrom – beslutsstöd för prioriteringar (2010); <https://www.socialstyrelsen.se/regler-och-riktlinjer/nationella-riktlinjer/slutliga-riktlinjer/depression-och-angest/>

- Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study: <https://www.nimh.nih.gov/funding/clinical-research/practical/stard/index.shtml>
- TLV - Cymbalta ingår även fortsättningsvis i högkostnadsskyddet med begränsning 2012; <https://www.tlv.se/beslut/beslut-lakemedel/begransad-subvention/arkiv/2012-05-08-cymbalta-ingar-aven-fortsattningsvis-i-hogkostnadsskyddet-med-begransning.html>
- TLV – genomgång av läkemedel mot depression (december 2008); <https://www.tlv.se/lakemedel/omprovning-av-lakemedel/avslutade-omprovningar-av-lakemedel/arkiv/2009-01-19-depression.html>
- US. Food and drug Administration (FDA); Celexa (citalopram hydrobromide): Drug Safety Communication - Abnormal Heart Rhythms Associated With High Doses (Posted 24th August 2011); <https://www.fda.gov/drugs/drug-safety-and-availability>
- Venlafaxine– Summary of basis for regulatory position (2006 - 2011) <https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency> (sök på venlafaxine så kommer olika sammanfattande riktlinjer upp)
- <https://crediblemeds.org/> (kontinuerligt uppdaterade hemsidor med listor över läkemedel med potentiell påverkan på QT-intervall med värdering av arytmirisk, dvs ffa torsade de pointes)
- US Food and Drug Administration (FDA): <https://www.fda.gov/drugs/drug-safety-and-availability/drug-alerts-and-statements>
- 2011-11-21: TLV:s utvärdering av förmånen beträffande duloxetin (Cymbalta): www.tlv.se/beslut/beslut-lakemedel/begransad-subvention/cymbaltas-uppfoljningsvillkor-uppfyllt
- <https://clinicaltrials.gov/>
- <https://www.ema.europa.eu/en>
- A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors <http://www.nature.com/tp/journal/v6/n6/abs/tp2016104a.html>

Neuropsykiatriska sjukdomstillstånd:

- Jankovic J: Tourette's syndrome, *N Engl J Med* 2001 Oct 18;345(16):1184-92; <http://www.nejm.org/doi/full/10.1056/NEJMra010032>
- Läkemedelsbehandling vid ADHD (Läkemedelsverket 2009); <https://lakemedelsverket.se/malgrupp/Halso---sjukvard/Behandlings--rekommendationer/Behandlingsrekommendation--listan/Adhd/>
- Silay YS; Jankovic J: Emerging drugs in Tourette syndrome, *Expert Opin Emerg Drugs*. 2005 May; 10(2):365-80; <http://www.tandfonline.com/doi/abs/10.1517/14728214.10.2.365>
- 2012-01-11: SBU rapport om bristfällig dokumentation vid utredning och behandling av ADHD & autism: <https://www.sbu.se/sv/publikationer/prioritering-av-vetenskapliga-kunskapsluckor/behandlingsmetoder-vid-adhd--de-tio-viktigaste-kunskapsluckorna/>
- SBU: Diagnostik och behandling av ADHD och autismspektrumtillstånd; <http://www.sbu.se/sv/publikationer/SBU-utvarderar/adhd-diagnostik-och-behandling-vardens-organisation-och-patientens-delaktighet/>
- ADHD och autismspektrumstörning i ett livsperspektiv : en klinisk introduktion till utvecklingsrelaterade kognitiva funktionsproblem Gunilla Thernlunds <http://www.tlv.se/>

Psykotiska symtom/schizofreni:

- Schizofreni – behandlingsrekommendation; Läkemedelsverket 2013 <https://lakemedelsverket.se/malgrupp/Halso---sjukvard/Behandlings--rekommendationer/Behandlingsrekommendation--listan/Schizofreni-1/>
- World Federation of Societies of Biological Psychiatry (WFSBP)
Guidelines for Biological Treatment of Schizophrenia, Part 2:
Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects; http://www.wfsbp.org/fileadmin/user_upload/Treatment_Guidelines/WFSP_SZ_Guidelines_Part2_2013.pdf
- Dixon, L et al: uppdatering av Guideline Watch (September 2009): APA Practice Guideline for the Treatment of Patients With Schizophrenia; http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/schizophrenia-watch.pdf
- Guidelines for Biological Treatment of Schizophrenia, part 1: Acute Treatment of Schizophrenia – 2005 (World Federation of Societies of Biological Psychiatry (WFSBP); *World J Biol Psychiatry* 2005;6(3):132-191; <http://www.tandfonline.com/doi/abs/10.1080/15622970510030090>

- Kane J M, Leucht S, Carpenter D, Docherty J P. The Expert Consensus Guideline Series: Optimizing Pharmacologic Treatment of Psychotic Disorders. *Journal of Clinical Psychiatry* 2003;64 (suppl 12):1-100; https://www.researchgate.net/publication/8989985_Expert_Consensus_Guidelines_for_Optimizing_Pharmacologic_Treatment_of_Psychotic_Disorders
- Msghina M et al: Antipsykotiska läkemedel väljs bäst efter biverkningsprofil; *Läkartidningen* nr 44 vol 106 2009;2841-46; <http://lakartidningen.se/>
- National Institute Of Clinical Excellence (NICE guideline update February 2014) CG178 Schizophrenia: Psychosis and schizophrenia in adults: prevention and management (NICE guideline) ; <https://www.nice.org.uk/guidance/cg178>
- Practice Guideline for The Treatment of Patients With Schizophrenia, Second Edition, American Psychiatric Association April 2004; <https://ohsu.pure.elsevier.com/en/publications/practice-guideline-for-the-treatment-of-patients-with-schizophrenia-2>
- SBU: Schizofreni – Läkemedelsbehandling, patientens delaktighet och vårdens organisation (20121121) ; <https://www.sbu.se/sv/publikationer/SBU-utvarderar/schizofreni-lakemedelsbehandling-patientens-delaktighet-och-vardens-organisation/>
- Svenska Psykiatriska Föreningens kliniska riktlinjer: Att förebygga och handlägga metabol risk hos patienter med allvarlig psykisk sjukdom; <http://www.svenskpsykiatri.se/wp-content/uploads/2017/02/SPF-kliniska-riktlinjer-om-metabol-risk.pdf>
- Svenska Psykiatriska Föreningens kliniska riktlinjer: Schizofreni - kliniska riktlinjer för utredning och behandling; <http://www.svenskpsykiatri.se/spfs-kliniska-riktlinjer/>
- Thelander Sten et al; Läkemedel mot schizofreni: SBU lyckas inte reda ut begreppen (jämte) Replik: SBU står fast - läkemedel räddar liv vid schizofreni av Mats Berglund, Eva Lindström, Mikael Nilsson, Måns Rosén *Läkartidningen* 2012 nr 32 sid 1417-9; <http://lakartidningen.se/>
- Antipsykotiska läkemedel: *läkartidningen*.2014;111:CY3U; <http://lakartidningen.se/>

Sömnstörning:

- (8) <https://www.regionorebrolan.se/Files-sv/Örebro%20läns%20landsting/Vård%20och%20hälsa/För%20vårdgivare/Läkemedelskommittén/För%20allmänheten/Somndagbok.pdf>
- Bliwise, D., W. Seidel, D. J. Greenblatt, and W. Dement. "Nighttime and Daytime Efficacy of Flurazepam and Oxazepam in Chronic Insomnia." [In eng]. *Am J Psychiatry* 141, no. 2 (Feb 1984): 191-5.
- Brunton, Laurence L. Goodman & Gilman's the Pharmacological Basis of Therapeutics [Elektronisk Resurs]. 2018.
- Debernard, K. A. B., J. Frost, and P. H. Roland. "Quetiapine Is Not a Sleeping Pill." [In eng nor]. *Tidsskr Nor Laegeforen* 139, no. 13 (Sep 24 2019).
- Feldmeier, C., and W. Kapp. "Comparative Clinical Studies with Midazolam, Oxazepam and Placebo." [In eng]. *Br J Clin Pharmacol* 16 Suppl 1 (1983): 151s-55s.
- Gallais, H., P. Casanova, and H. Fabregat. "Midazolam and Oxazepam in the Treatment of Insomnia in Hospitalized Patients." [In eng]. *Br J Clin Pharmacol* 16 Suppl 1 (1983): 145s-49s.
- Goodman, Louis Sanford, Alfred Goodman Gilman, Laurence L. Brunton, Carolina Kockum Lybeck, Peter Carlsson, Sus Andersson, and Johan Öhman. Goodman & Gilman's the Pharmacological Basis of Therapeutics [Ljudupptagning]. Johanneshov: MTM, 2014.
- Gotestam, K. G., F. Oppoyen, and D. Berntzen. "Treatment of Insomnia with Two Benzodiazepines: A Double-Blind Crossover Study." [In eng]. *Eur J Clin Pharmacol* 41, no. 2 (1991): 137-40.
- Roehrs, T. A., S. Randall, E. Harris, R. Maan, and T. Roth. "Twelve Months of Nightly Zolpidem Does Not Lead to Dose Escalation: A Prospective Placebo-Controlled Study." [In eng]. *Sleep* 34, no. 2 (Feb 1 2011): 207-12.
- Wilby, M. J., and P. J. Hutchinson. "The Pharmacology of Chlormethiazole: A Potential Neuroprotective Agent?". *CNS Drug Reviews* 10, no. 4 (2004): 281-94.
- <https://lakemedelsverket.se/malgrupp/Halso--sjukvard/Behandlings--rekommendationer/Behandlingsrekommendation--listan/Somnstorningar-hos-barn/>.
- <https://janusinfo.se/behandling/expertgruppsutlatanden/aldreshalsa/aldreshalsa/klok-lakemedelsbehandling-av-demestsjuka-aldre/bakgrunds-material/somnstorningar.5.3da1c377162bd90d9ee9366.html>
- <https://janusinfo.se/behandling/expertgruppsutlatanden/psykiskhalsa.4.728c0e316219da8135bd883.html>
- Christoffer RAHM, *Neurovetenskaplig psykiatri*, upplaga 1, Natur Kultur Akademisk, 2018
- Lars Olson, Anna Josephson. *Hjärnan*, upplaga 1, Karolinska Institutet, 2012
- Stephen M Stahl, *Stahl's Essential Psychopharmacology*, Cambridge University Press, 2013

Ångestsyndrom (inkl tvångssyndrom och posttraumatiskt stressyndrom)

- Allgulander, C et al: Nyttan och risker med bensodiazepiner. Aktuell faktaanlys Läkartidningen 2011 nr 41 sid 2025-9; <http://lakartidningen.se/>
- Depression, ångestsyndrom och tvångssyndrom hos barn och vuxna – behandlingsrekommendation Läkemedelsverket 2016; <https://lakemedelsverket.se/malgrupp/Halso---sjukvard/Behandlings--rekommendationer/Behandlingsrekommendation---listan/Depression-angestsyndrom-och-tvangssyndrom-hos-barn-och-vuxna/>
- Socialstyrelsen: Nationella riktlinjer för depressionssjukdom och ångestsyndrom – beslutsstöd för prioriteringar (2010); <https://www.socialstyrelsen.se/regler-och-riktlinjer/nationella-riktlinjer/slutliga-riktlinjer/depression-och-angest/>
- Ångestsjukdomar hos barn och ungdomar – hjälp finns att få; Läkartidningen nr 43-44 Oktober 2012; 1946-49; <http://lakartidningen.se/>
- Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder:
- A revision of the 2005 guidelines from the British Association for Psychopharmacology <http://journals.sagepub.com/doi/full/10.1177/0269881114525674>
- Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders (review) <http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD005473.pub2/full>

Skattningsskalor Ångest

- <https://www.fbanken.se/> :
- https://fbanken.se/files/273/PCL-5_med_kriterium_A_SVENSKA.pdf
- https://www.fbanken.se/files/117/BOCS_svensk.pdf
- https://www.fbanken.se/files/218/GAD7_Swedish_for_Sweden.pdf
- <https://www.fbanken.se/files/34/LSAS-SR.pdf>
- <https://fbanken.se/files/27/panikdagbok.pdf>

Referenser Smärta

Akut smärta

- Oxford league table of analgesics in acute pain (2007). Bandolier.
- Lesko SM, Mitchell AA. An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial. *JAMA* 1995;273(12):929-33.
- Oxycodone for the treatment of postoperative pain. Kokki H, Kokki M, Sjövall S. *Expert Opin Pharmacother*. 2012 May;13(7):1045-58. Review. PMID: 22519769 [PubMed - indexed for MEDLINE] Related citations
- Long-acting morphine following hip or knee replacement: a randomized, double-blind and placebo-controlled trial. Musclow SL, Bowers T, Vo H, Glube M, Nguyen T. *Pain Res Manag*. 2012 Mar-Apr;17(2):83-8. PMID: 22518369 [PubMed - indexed for MED- LINE] Related citations
- Lin J, et al. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. *BMJ*. 2004;329(7461):324.
- Mason L, et al. Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis. *BMC Musculoskelet Disord*. 2004;5(1):28.
- Nabulsi M, Tamim H, Sabra R, Mahfoud Z, Malaeb S, Fakh H, Mikati M. Equal antipyretic effectiveness of oral and rectal acetaminophen: a randomized controlled trial. *BMC Pediatr*. 2005;5:35.
- Perrott DA, Piira T, Goodenough B, Champion GD. Efficacy and safety of acetaminophen vs ibuprofen for treating children's pain or fever: a meta-analysis. *Arch Pediatr Adolesc Med* 2004;158(6):521-6.

Långvarig smärta, allmänt

- Artros. Behandling av artros. Läkemedelsverket och Statens Legemiddelverk. Information från Läkemedelsverket 2004;15(3):19-75. www.lakemedelsverket.se (Hälsa- och sjukvård/ Behandlingsrekommendationer/Artros)
- SBU rapport nr 177 (2006). Metoder för behandling av långvarig smärta. En systematisk litteraturöversikt. www.sbu.se
- Läkemedelsbehandling av långvarig smärta hos barn och vuxna – behandlingsrekommendation. Information från Läkemedelsverket 2017;28(3):23–53.

Långvarig smärta, COX-hämmare

- Bresalier RS et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. *N Engl J Med* 2005;352:1092-102.
- Chan FK et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. *N Engl J Med* 2002;347:2104-10.
- Chan FK et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. *Gastroenterology*. 2004;127:1038-43.
- Chan FK, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. *Lancet* 2007;369(9573):1621-6.
- Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. *Br J Clin Pharmacol*. 2003;55(6):591-5.
- Coxib and Traditional NSAID Trialists' Collaboration. The Lancet ;Early Online Publication, 30 May 2013. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. *The Lancet*.
- EMEA (European Medicines Agency): CHMP review on non-selective non-steroidal anti-inflammatory drugs (NSAIDs). Opinion, and Appendix II. EMEA/CHMP/410051/2006. (verifierat 2006- 12-06)
- Helin-Salmivaara A, et al. Risk of upper gastrointestinal events with the use of various NSAIDs: a casecontrol study in a general population. *Scand J Gastroenterology* 2007;42:923-32 (a)
- Helin-Salmivaara A, et al. Risk of serious upper gastrointestinal events with concurrent use of NSAIDs and SSRIs: a case-control study in the general population. *Eur J Clin Pharmacol* 2007;63:403-6 (b)
- Hooper L, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. *BMJ*. 2004;329(7472):948.

- Lin J, et al. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. *BMJ*. 2004;329(7461):324.
- Mason L, et al. Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis. *BMC Musculoskelet Disord*. 2004;5:28.
- Rostom et al. Prevention of NSAID-induced gastroduodenal ulcers (Cochrane Review). In: *The Cochrane Library*, Issue 4, 2002. Oxford: Update Software. (Date of most recent substantive amendment: 24 August 2004)
- Solomon SC et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. *N Engl J Med* 2005;352:1071-80.
- Tata LJ et al. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? *Aliment Pharmacol Ther*. 2005;22(3):175-81.
- Towheed TE et al. Acetaminophen for osteoarthritis. *Cochrane Database Syst Rev*. 2006 Jan 25;(1):CD004257.
- Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. *N Engl J Med*. 2016 Dec 29;375(26):2519-29

Långvarig smärta, opioider

- Davis MP et al. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy (Review). *Support Care Cancer* 2003;22:84-92.
- Opioider. Användning av opioider vid långvarig icke-cancerrelaterad smärta. Läkemedelsverket och Statens Legemiddelverk. Workshop. Information från Läkemedelsverket 2002 (1): 17 -75. www.lakemedelsverket.se
- Reid CM, et al. Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials. *Arch Intern Med* 2006;166(8):837-43.
- Riley et al. No pain relief from morphine? *Support Care Cancer* (2006) 14:56–64. Oral morphine for cancer pain (Review). *The Cochrane Collaboration* 2009, Issue 3.
- https://lakemedelsboken.se/kapitel/mage-tarm/tarmkanalens_funktionsrubbnings.html

Neuropatisk smärta

- Attal N, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. *Eur J Neurol*. 2006;13(11):1153-69.
- Finnerup NB Nyare finns från 2010 et al. Algorithm for neuropathic pain treatment: An evidence based proposal. *Pain*. 2005;118(3):289-305.
- Hempenstall K et al. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. *PLoS Med* 2005;2(7):e164.
- Neuropatisk smärta. Behandlingsrekommendationer. Läkemedelsverket 2007. Läkemedelsverket 2017
- Cannabis-based medicines for chronic neuropathic pain in adults. *Cochrane Database Syst Rev*. 2018 Mar; 2018(3): CD012182)

Smärtlindrande läkemedel till äldre

- Bannwarth B et al. Single and multiple dose pharmacokinetics of acetaminophen (paracetamol) in polymedicated very old patients with rheumatic pain. *J Rheumatol*. 2001;28(1):182-4.
- Davis MP, et al. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy (Review). *Support Care Cancer* 2003;22:84-92.
- Opioids and the Management of Chronic Severe Pain in the Elderly: Consensus Statement of an International Expert Panel with Focus on the Six Clinically Most Often Used World Health Organization step III Opioids. *World Institute of Pain. Pain Practice*, Volume 8, issue 4, 2008 287 – 313
- Review of opioid efficacy in pain management in the elderly. Consensus statement Opioids and the Management of Chronic Severe Pain in the Elderly *Pain Practice*, Volume 8, Issue 4, 2008 287– 313

Utsättning av smärtläkemedel

- Haddad PM. Antidepressant discontinuation syndromes. *Drug Saf.* 2001;24:183-97. Norton JW. Gabapentin withdrawal syndrome. *Clin Neuropharmacol.* 2001;24:245-6.
- Persson M et al. Utsättningsreaktioner av tramadol – ett större problem än förväntat? Läkemedelsverket 2006-11-14, www.lakemedelsverket.se (2006-12-06)
- Pittenger C, Desan PH. Gabapentin abuse, and delirium tremens upon gabapentin withdrawal. *J Clin Psychiatry.* 2007;68(3):483-4. Tran KT et al. Gabapentin withdrawal syndrome in the presence of a taper. *Bipolar Disord.* 2005;7(3): 302-4.
- Barrueto F Jr et al. Gabapentin withdrawal presenting as status epilepticus. *J Toxicol Clin Toxicol.* 2002; 40(7):925-8. Norton JW. Gabapentin withdrawal syndrome. *Clin Neuropharmacol.* 2001;24(4):245-6. FAS UT 2 Claes Lundgren

Referenser Urologi

1. <https://vardgivare.skane.se/vardriktlinjer/kvinnosjukdomar-och-forlossning/ako/urininkontinens-hos-kvinnor/?highlight=urininkontinens+kvinnor>
2. <https://vardgivare.skane.se/vardriktlinjer/njur-och-urinvagssjukdomar/ako/nokturi-och-nokturn-polyuri/?highlight=nokturi>
3. <https://vardgivare.skane.se/vardriktlinjer/njur-och-urinvagssjukdomar/ako/erektil-dysfunktion>
4. Uvelius et al. Läkartidningen 8/2020
5. <https://vardgivare.skane.se/vardriktlinjer/njur-och-urinvagssjukdomar/ako/erektil-dysfunktion/>
6. <https://vardgivare.skane.se/vardriktlinjer/njur-och-urinvagssjukdomar/ako/benign-prostatahyperplasi/?highlight=benign%2Bprostata%2Bhyperplasi>
7. deReike & Klarskov. BJU Int;2004;93:757
8. Fourcade. Prog urol. 2000;10:246
9. <https://vardgivare.skane.se/vardriktlinjer/cancer/ako/prostatacancer/>
10. <https://www.cancercentrum.se/samverkan/cancerdiagnoser/prostata/vardforlopp/>
11. Chapple et al. Eur Urol 2008;54:543
12. Novara et al. Eur Urol 2008; 54:740
13. Kaplan et al. BJU Int 2011; 107:1432
14. Meek et al. Dig Dis Sci 2011; 56:7
15. Paquette et al. J Am Geriatr Soc 2011; 59:1332
16. Roehrborn et al. Urology 1999; 53:581
17. Porst et al. Urology 2013; 82:667
18. Giuliano et al. J Sex Med 2013; 10:857
19. deReike & Klarskov. BJU Int;2004;93:757
20. Fourcade. Prog urol. 2000;10:246
21. Perachino et al. BJU Int 2010 ;105 :648
22. Morote et al. J Urol 2007;178:1290
23. Lenhard et al. Data on file. Sandoz A/S Danmark

Referenser Äldre – särskilda rekommendationer

(1) <https://vardgivare.skane.se/vardriktlinjer/lakemedel/#94422>

(2) <https://vardgivare.skane.se/vardriktlinjer/lakemedel/lakemedelssakerhet/>

Socialstyrelsen. 2017. Indikatorer för god läkemedelsterapi hos äldre. Art. No. 2017-6-7. www.socialstyrelsen.se

Orostillstånd hos äldre

NICE. 2011. Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults Management in primary, secondary and community care. NICE clinical guideline 113.

SBU. Statens beredning för medicinsk utvärdering. 2005. Behandling av ångestsyndrom. En systematisk litteraturoversikt. Rapportnr 177 (volym 1).

Sömn och äldre

SBU. Statens beredning för medicinsk utvärdering. 2010. Behandling av sömnbesvär hos vuxna. En systematisk litteraturoversikt. Rapportnr 199.

Buscemi et al., The Efficacy and Safety of Exogenous Melatonin for Primary Sleep Disorders A Meta-Analysis. *J Gen Intern Med* 2005; 20:1151–1158.

Kanji S et. al., Pharmacological interventions to improve sleep in hospitalised adults: a systematic review. <https://www.ncbi.nlm.nih.gov/pub-med/27473952> *BMJ Open*. 2016 Jul 29;6(7).

Scholtens R.M. et al., Physiological melatonin levels in healthy older people: A systematic review. *Journal of Psychosomatic Research* 86 (2016) 20–27

Vural E. M. S. et.al., Optimal Dosages for Melatonin Supplementation Therapy in Older Adults: A Systematic Review of Current Literature. *Drugs Aging* (2014) 31:441–451.

Depression hos äldre

SBU. Statens beredning för medicinsk utvärdering. 2015. Behandling av depression hos äldre. En systematisk litteraturoversikt. Rapportnr 233.

Taylor WD. Clinical practice. Depression in the elderly. 2014. *N Engl J Med* 371 (13): 1228-36. doi: 10.1056/NEJMcp1402180

Äldre och fysisk aktivitet

Yrkesföreningar för Fysisk aktivitet. FYSS 2015 http://www.fyss.se/wp-content/uploads/2017/09/FYSS-kapitel_FA_aldre_FINAL_2016-12.pdf

Läkemedel och äldre

Annika Kragh et al. Äldres läkemedelsbehandling. Studentlitteratur. 2013.

Grubb A. Non-invasive estimation of glomerular filtration rate (GFR). The Lund model: Simultaneous use of cystatin C- and creatinine-based GFR-prediction equations, clinical data and internal quality check. 2010. *Scand J Clin Lab Invest* 2010; 70: 65-70.

Lundgren, C. FAS UT 3. Att utvärdera, ifrågasätta och skonsamt avsluta läkemedelsbehandling. Läkemedelskommittén i Västerbottens läns landsting. 2010. www.fasut.nu

SBU Statens beredning för medicinsk utvärdering. 2009. Äldres läkemedelsanvändning – Hur kan den förbättras? Rapportnr 193.

Socialstyrelsen. 2011. Kvaliteten i äldres läkemedelsanvändning - Läkarens roll. Art. No 2011-6-12. www.socialstyrelsen.se

Socialstyrelsen. 2014. Läkemedelsorsakad sjuklighet hos äldre - Kartläggning och förslag till åtgärder. Art. No 2014-12-13. www.socialstyrelsen.se

Läkemedel och fall

Cameron ID, Murray GR et al. Interventions for preventing falls in older people in nursing care facilities and hospitals (Review). Cochrane Database Syst Rev 2010, Issue 1. Art No: CD005465. DOI:10.1002/14651858.CD005465.pub2.

Gillespie LD, Gillespie WJ et al. Interventions for preventing falls in elderly people. Cochrane Database Syst Rev 2009; 2; No: CD000340. DOI:10.1002/14651858.CD000340.pub2.

Gillespie LD, Robertson MC et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2009, Issue 2. Art No: CD007146. DOI: 10.1002/14651858.CD007146.pub2.

Tinetti ME, Richman D et al. Falls efficacy as a measure of fear of falling. J Gerontol 1990; 45: 239-43.

Urologiska spasmolytika

Chapple C, Khullar V et al. The effects of antimuscarinic treatment in overactive bladder: a systematic review and meta-analysis. Eur Urology 2005;48: 5–26.

Glavind K, Chancellor M. Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity. Int Urogynecol J 2011; 22: 907–17.

Fox C, Richardson K et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc 2011; 59: 1477-83.

Hijaz A, Rackley R. Treating Overactive Bladder in the Elderly: Side-Effect Profiles of Anticholinergic Drugs. 2011-11-16, from http://www.ger-uro.ru/mod_files/pub_mater/s16/s16.doc

Läkemedelsverket. Behandling av urinträngningar och trängningsinkontinens – överaktiv blåsa. Information från Läkemedelsverket 2011; 22: 12-21.

NICE 2013. Mirabegron for treating symptoms of overactive bladder. NICE technology appraisal guidance 290, from guidance.nice.org.uk/ta290

Läkemedelsgenomgångar

Milos V, Rekman E et al. Improving the quality of pharmacotherapy in elderly primary care patients through medication reviews: a randomised controlled study. Drugs Aging. 2013 Apr;30(4):235-46.

Hellström LM, Bondesson Å et al. Impact of the Lund Integrated Medicines Management (LIMM) model on medication appropriateness and drug-related hospital revisits. Eur J Clin Pharmacol. 2011 Jul;67(7):741-52.

Referenser Öron

Öron

1. Heslop A, Lildholdt T, Gammelgaard N, Ovesen T. Topical ciprofloxacin is superior to topical saline and systemic antibiotics in the treatment of tympanostomy tube otorrhea in children: the results of a randomized clinical trial. *Laryngoscope*. 2010 Dec;120(12):2516-20.
2. SBU. Rörbehandling vid inflammation i mellanörat. En systematisk litteraturoversikt. Stockholm: Statens beredning för medicinsk utvärdering (SBU); 2008. SBU-rapport nr 189. ISBN 978-91-85413-22-5.
3. van Dongen TM, van der Heijden GJ, Venekamp RP, Rovers MM, Schilder AG. A trial of treatment for acute otorrhea in children with tympanostomy tubes. *N Engl J Med* 2014 Feb 20;370(8):723-33. Bakgrundsdokumentation. Uppdatering av behandlings-rekommendation rörotit. Juni 2018. Tillhör Behandlingsrekommendation diagnostik, behandling och uppföljning av akut mediaotit från 2010.